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A B S T R A C T
Background
Anti-fungals are available for oral and intra-vaginal treatment of uncomplicated vulvovaginal candidiasis.
Objectives
The primary objective of this review is to assess the relative eDectiveness (clinical cure) of oral versus intra-vaginal anti-fungals for the
treatment of uncomplicated vulvovaginal candidiasis. Secondary objectives include the assessment of the relative eDectiveness in terms
of mycological cure, in addition to safety, side eDects, treatment preference, time to first relief of symptoms, and costs.
Search methods
We searched CENTRAL, MEDLINE, Embase, and two trials registers on 29 August 2019 together with reference checking and citation
searching.
Selection criteria
We included randomised controlled trials published in any language comparing at least one oral anti-fungal with one intra-vaginal anti-
fungal in women (aged 16 years or over) with a mycological diagnosis (positive culture, microscopy for yeast, or both) of uncomplicated
vulvovaginal candidiasis. We excluded trials if they solely involved participants who were HIV positive, immunocompromised, pregnant,
breast feeding or diabetic.
Data collection and analysis
We used standard methodological procedures as recommended by Cochrane.
Main results
This review includes 26 trials (5007 participants). Eight anti-fungals are represented. All but three trials included participants with acute
vulvovaginal candidiasis. Trials were conducted in Europe: UK (3), Croatia (2). Finland (2), the Netherlands (2), Germany (1), Italy (1), Sweden
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(1) and one trial across multiple European countries, USA (7) Thailand (2), Iran (2), Japan (1) and Africa (Nigeria) (1). The duration of follow-
up varied between trials. The overall risk of bias of the included trials was high.
There was probably little or no diDerence shown between oral and intra-vaginal anti-fungal treatment for clinical cure at short-term follow-
up (OR 1.14, 95% CI 0.91 to 1.43; 13 trials; 1859 participants; moderate-certainty evidence) and long-term follow-up (OR 1.07, 95% CI 0.77
to 1.50; 9 trials; 1042 participants; moderate-certainty evidence). The evidence suggests that if the rate of clinical cure at short-term follow-
up with intra-vaginal treatment is 77%, the rate with oral treatment would be between 75% and 83%; if the rate of clinical cure at long
term follow-up with intra-vaginal treatment is 84%, the rate with oral treatment would be between 80% and 89%. Oral treatment probably
improves mycological cure over intra-vaginal treatment at short term (OR 1.24, 95% CI 1.03 to 1.50: 19 trials; 3057 participants; moderate-
certainty evidence) and long-term follow-up (OR 1.29, 95% CI 1.05 to 1.60; 13 trials; 1661 participants; moderate-certainty evidence).
The evidence suggests that if the rate of mycological cure at short-term follow-up with intra-vaginal treatment is 80%, the rate with oral
treatment would be between 80% and 85%; if the rate of mycological cure at long-term follow-up with intra-vaginal treatment is 66%, the
rate with oral treatment would be between 67% and 76%.
In terms of patient safety, there is a low risk of participants withdrawing from the studies due to adverse drug eDects for either treatment
(23 trials; 4637 participants; high-certainty evidence). Due to the low certainty of evidence, it is undetermined whether oral treatments
reduced the number of side eDects compared with intra-vaginal treatments (OR 1.04, 95% CI 0.84 to 1.29; 16 trials; 3155 participants; low-
certainty evidence). The evidence suggests that if the rate of side eDects with intra-vaginal treatment is 12%, the rate with oral treatment
would be between 10% and 15%. We noted that the type of side eDects diDered, with intra-vaginal treatments being more oMen associated
with local reactions, and oral treatments being more oMen associated with systemic eDects including gastro-intestinal symptoms and
headaches. Oral treatment appeared to be the favoured treatment preference over intra-vaginal treatment or no preference (12 trials; 2206
participants), however the data were poorly reported and the certainty of the evidence was low. There was little or no diDerence in time to
first relief of symptoms between oral and intra-vaginal treatments: four trials favoured the oral treatment, four favoured intra-vaginal, one
study reported no diDerence and one was unclear. The measurements varied between the 10 trials (1910 participants) and the certainty
of the evidence was low. Costs were not reported in any of the trials.
Authors' conclusions
Oral anti-fungal treatment probably improves short- and long-term mycological cure over intra-vaginal treatment for uncomplicated
vaginal candidiasis. Oral treatment was the favoured treatment preference by participants, though the certainty of this evidence is low.
The decision to prescribe or recommend an anti-fungal for oral or intra-vaginal administration should take into consideration safety in
terms of withdrawals and side eDects, as well as cost and treatment preference. Unless there is a previous history of adverse reaction to
one route of administration or contraindications, women who are purchasing their own treatment should be given full information about
the characteristics and costs of treatment to make their own decision. If health services are paying the treatment cost, decision-makers
should consider whether the higher cost of some oral anti-fungals is worth the gain in convenience, if this is the patient's preference.
P L A I N   L A N G U A G E   S U M M A R Y
Do antifungal medicines for vaginal yeast infections (thrush) work better if taken by mouth (orally) or placed in the vagina
(intravaginally)?
What is thrush?
Thrush (also called candidiasis) is a common vaginal infection caused by a type of fungus called a yeast. Symptoms include itching and
irritation around the vagina and a white discharge. Thrush is usually harmless but it can be uncomfortable.
Thrush is usually treated with antifungal medicines. These can be taken by mouth (orally) or placed in the vagina (intravaginally).
Why we did this Cochrane Review
We wanted to find out if oral antifungal medicines work better than intravaginal antifungal medicines to treat thrush infections.
What did we do?
We searched for studies of antifungal medicines to treat thrush that compared an oral antifungal with an intravaginal antifungal.
We looked for randomised controlled studies, in which the treatments received were decided at random, because these studies usually
give the most reliable evidence about the eDects of treatments.
We were interested in how well - and how fast - antifungal medicines could get rid of yeast infections and improve symptoms; whether they
had any unwanted eDects; and whether women preferred oral or intravaginal treatment.
Search date: we included evidence published up to 29 August 2019.
What we found
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We found 26 studies in 5007 women with thrush who were treated with antifungal medicines called azoles. The studies were conducted
in Europe, the USA, Thailand, Iran, Japan and Nigeria. Eight azoles were studied: 2 oral (fluconazole and itraconazole) and 6 intravaginal
(butoconazole, clotrimazole, econazole, miconazole, sertaconazole and terconazole).
The studies measured whether oral and intravaginal antifungal medicines led to:
• no symptoms (clinical cure);
• no yeasts found in the vagina (mycological cure); or
• unwanted eDects that caused women to stop treatment.
No studies reported the costs of the oral or intravaginal antifungal medicines.
What are the results of our review?
Clinical cure (no symptoms) was similar for oral and intravaginal antifungal medicines in both the short term (5 to 15 days; 13 studies),
and long term (2 to 12 weeks; 9 studies). Whether an antifungal medicine is oral or intravaginal probably makes little to no diDerence to
getting rid of thrush symptoms.
However, oral antifungal medicines probably cleared yeast from the vagina (mycological cure) better than intravaginal ones in both the
short term (19 studies) and long term (13 studies).
Only three women stopped using their antifungal medicine because of unwanted eDects (23 studies); the risk of women stopping treatment
with oral or intravaginal antifungal medicines is low.
The numbers of unwanted eDects reported were similar: whether an antifungal medicine is oral or intravaginal might make little to
no diDerence to unwanted eDects (13 studies). Headache and digestive symptoms were more common with oral antifungal medicines;
unwanted eDects of intravaginal antifungals commonly aDected only the vaginal area.
Our results suggested that women might prefer taking an oral antifungal medicine to an intravaginal one (12 studies).
Whether an antifungal medicine is oral or intravaginal may make little to no diDerence to how quickly thrush gets better.
How reliable are these results?
We are moderately confident in our findings for clinical and mycological cure of thrush. These results might change if further evidence
becomes available. We are confident about the low risk of women stopping treatment because of unwanted eDects of antifungal medicines,
and further evidence is unlikely change this.
We are less confident about the numbers of unwanted eDects, preferred treatment, and how quickly symptoms get better. These results
are likely to change if further evidence becomes available.
Ten studies received support from pharmaceutical companies; this could have aDected how the studies were designed, conducted and
reported. The results from some studies varied widely and were not reported consistently; and the women knew which treatment they
had, which could have aDected the results reported.
Conclusions
Oral antifungal medicines probably clear yeast from the vagina better than intravaginal antifungal medicines, although there is probably
little to no diDerence between them for getting rid of thrush symptoms.
The risk of women stopping treatment because of unwanted eDects is low for both oral and intravaginal antifungal medicines.
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S U M M A R Y   O F   F I N D I N G S
 
Summary of findings 1.   Oral versus intra-vaginal antifungal treatment of uncomplicated vulvovaginal candidiasis
Oral versus intra-vaginal antifungal treatment of uncomplicated vulvovaginal candidiasis.
Patient or population: women aged 16 and over with uncomplicated vulvovaginal candidiasis
Settings: various settings (single and multi-centre obs/gyn or other outpatient clinics) in Europe, USA, Japan, Thailand, Iran, Africa/Nigeria
Intervention: oral antifungal treatment of uncomplicated vulvovaginal candidiasis (fluconazole and itraconazole)



















































































































































































































































































Measured by number of withdrawals due to adverse reactions. Three trials reported with-
drawals due to adverse drug reactions (one participant in each trial). Two withdrawals
were from the intra-vaginal treatment group (both miconazole ACCELERATE 2002; Timo-

















Three trials were not included in the meta-analysis because they did not provide any in-
dication of the direction or magnitude of the relative treatment effect, as they reported
there were no side effect events for either treatment group (Mikamo 1995; Škerk V 2006;
Slavin 1992) Two further trials were also not included in the meta-analyses because they
did not provide numerical data about side effect events (Goode 1992; Roongpisuthipong








Poorly reported. Unable to determine preference in one trial (Tobin 1992). One study re-
ported no preference (Van Heusden 1990).
10/12 studies preferred oral treatment (compared with intra-vaginal or no preference)
Time to first relief
of
symptoms




Time to first relief measurements varied between studies. Four trials favoured intra-vagi-
nal (ACCELERATE 2002; Murina 2012;Seidman 2005; Slavin 1992. Two trials reported little
or no difference (Adetoro 1990; Mendling 2004), and one study showed mixed effects (Ti-
monen 1992a)
Costs Not reported in any study -
*The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95%
CI).
CI: Confidence interval; OR: Odds ratio;RCT: Randomised controlled trial.
High certainty: we are very confident that the true effect lies close to that of the estimate of the effect.
Moderate certainty: we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different.
Low certainty: our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.
Very low certainty: we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect.
1 Downgraded 1 level for serious concern for risk of bias.
2 Downgraded 1 level for substantial heterogeneity across and within subgroups.
3 Downgraded 1 level for inconsistencies associated with reporting.
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B A C K G R O U N D
Description of the condition
Previous estimates suggest that 75% of women experience at
least one episode of vulvovaginal candidiasis (thrush) before the
menopause (Sobel 2007). Candidiasis is the term that is used
generically for vaginal infections produced by Candida species.
Candida albicans (C. albicans) is the species most oMen associated
with candidiasis, however, other yeasts (e.g. C. glabrata, C. krusei)
can also cause this infection (Gonçalves 2016).
Description of the intervention
Vulvovaginal candidiasis is treated with a variety of anti-fungal
drugs (Martindale 2017) that are administered by the oral or local
(intra-vaginal) route. The decision to use a specific anti-fungal
depends upon its safety, eDectiveness, cost and patient preference.
How the intervention might work
There are several classes of anti-fungals with various molecular
targets and modes of action (Odds 2003). Therapy for vaginal
infection is dominated by the azole class, which includes both oral
and intra-vaginal drugs (Pappas 2004). Azoles work by inhibiting
the synthesis of fungal lipids, especially ergosterol, which results
in damage to the cell membrane leading to cell death (Ghannoum
1999).
Why it is important to do this review
This review was last updated in 2007. Since then, the pattern
of resistance to antifungals could have changed, and as such it
is important to identify and include new studies that have been
conducted in contemporary populations.
O B J E C T I V E S
The primary objective of this review is to assess the relative
eDectiveness (clinical cure) of oral versus intra-vaginal anti-fungals
for the treatment of uncomplicated vulvovaginal candidiasis.
Secondary objectives include the assessment of the relative
eDectiveness in terms of mycological cure, in addition to safety, side
eDects, treatment preference, time to first relief of symptoms and
costs.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomised controlled trials irrespective of
publication type or language.
Types of participants
Women (aged 16 years or over) with uncomplicated vulvovaginal
candidiasis. For the purpose of this review, uncomplicated
vaginal candidiasis refers to acute episodes of this infection
(i.e. less than four episodes in 12 months). The diagnosis of
vulvovaginal candidiasis was confirmed mycologically (i.e. a
positive culture or microscopy, or both for yeast). Studies were
excluded if they solely involved participants who were HIV positive,
immunocompromised, pregnant, breast feeding or diabetic. Trials
that randomised participants with acute and chronic infections
were included if the results for the participants with acute infection
were presented separately, or, if less than 20% of participants had
chronic vaginal candidiasis.
Types of interventions
• Trials that compared any of the imidazole or
triazole anti-fungal drugs administered by the intra-
vaginal route (butoconazole, clotrimazole, econazole,
fenticonazole, isoconazole, miconazole, omoconazole,
oxiconazole, sertaconazole, terconazole, and tioconazole)
with orally administered imidazole or triazole anti-fungals
(fluconazole, itraconazole).
• Trials that compared more than two anti-fungals were included
if they compared oral and intra-vaginal routes of administration,
with each two-way comparison (i.e. oral versus intra-vaginal)
being treated separately.
We excluded trials that involved ketoconazole (oral and intra-
vaginal) due to its limited licence in many countries.
Types of outcome measures
Primary outcomes
• Clinical cure of the infection, both short (5 to 15 days) and long
term (2 to 12 weeks), as measured by the disappearance of
symptoms either on examination or by self-report
Secondary outcomes
• Mycological cure; both short (5 to 15 days) and long term (2
to 12 weeks) as determined by laboratory test(s) indicating
no presence of vulvovaginal candidiasis either by mycological
culture or microscopy
• Safety: as measured by the number of patient withdrawals due
to adverse reactions
• Side eDects: incidence of self-reported adverse reactions
(sometimes reported as side eDects)
• Treatment preference (of route of administration): measured by
self-report
• Time to first relief (of symptoms): measured by self-report
• Costs
Search methods for identification of studies
Electronic searches
We searched the following electronic databases on 29 August 2019:
• Cochrane Central Register of Controlled Trials (CENTRAL; 2019,
Issue 8) in the Cochrane Library;
• MEDLINE Ovid (including Epub Ahead of Print, In-Process &
Other Non-Indexed Citations and Versions) (1946 onwards);
• Embase Ovid (1974 to 29 August 2019);
Search strategies are comprised of keywords and controlled
vocabulary terms. The development of the final search strategy was
done with the assistance of Maria Teresa Vallejo, the Information
Specialist for the Sexually Transmitted Infections Cochrane Review
Group. We included studies regardless of publication type or
language of publication. Detailed search strategies are included in
Appendix 1.
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Searching other resources
In addition, we searched WHO ICTRP and ClinicalTrials.gov for
ongoing trials. We also handsearched the reference lists of any
relevant systematic reviews retrieved via the electronic searches.
Data collection and analysis
Selection of studies
For this update, pairs of review authors from HD, JO, JW, MCW and
MES independently read all the titles and abstracts retrieved from
the electronic searches to identify potentially eligible publications.
We retrieved full-text papers for all selected publications. Two
review authors from HD, JO, JW, MCW and MES independently
assessed their eligibility against the inclusion criteria. We selected
studies for the review according to the prespecified inclusion
criteria and resolved disagreements by discussion. We collated
multiple reports for the same study, so that each study rather than
each report is the unit of interest
Data extraction and management
Two review authors from HD, JO, JW, MCW and MES independently
completed data extraction capturing data on the following
characteristics and outcomes of each trial:
• the anti-fungal used, dose, frequency and duration of
administration;




Assessment of risk of bias in included studies
Two review authors from AM, HD, JO, JW and MES independently
assessed the risk of bias for each included study using the Cochrane
'Risk of bias' tool as outlined in Chapter 8 of the Cochrane Handbook
for Systematic Reviews of Interventions (Higgins 2017). We scored
each criterion, for each study, as low risk, unclear risk, or high
risk of bias and used the following determinations/consideration
when making our judgments for these domains. We resolved any
disagreements by discussion.
• Random allocation of treatment: "low risk" if a random process
was used (e.g. random numbers), or if the authors stated
explicitly that the trial groups were generated by random
allocation.
• Allocation concealment: "low risk" if the unit of randomisation
was by patient or episode of care, and some form of
centralised randomisation scheme was used (e.g. sealed opaque
envelopes).
• Blinding of participants and personnel: "low risk" if participants
would be blinded to whether they were getting oral or
vaginal interventions (e.g. received both treatments with one a
placebo).
• Blinding of outcome assessors to participants' assignment
status: "low risk" if the authors stated explicitly that the outcome
measures were assessed blindly. For clinical outcomes and
time to first relief, blinding was reported as "high risk" if the
patients could influence the findings by biased reporting. For
mycological outcomes, blinding was reported as "low risk" if
these were derived from objective tests and not influenced by
the patient or assessor.
• Incomplete outcome data: "high risk" if greater than 10% of
participants who were culture positive for yeast were lost to
follow-up. The follow-up of the longest duration was used for
this assessment.
• Selective reporting: "low risk" if reported the results of all
outcomes measured.
• Other potential sources of bias: "low risk" if there were no other
sources of bias identified.
Measures of treatment e;ect
The primary analysis was a comparison of the relative eDectiveness
of oral versus intra-vaginal anti-fungals for each outcome described
in the Types of outcome measures. We undertook meta-analyses
using a fixed-eDect model to pool the odds ratios of trials that were
homogenous in terms of the outcome measures that were used or
that could be calculated. Where it was not possible to undertake a
meta-analysis, we report the eDects in narrative.
If there were multiple intervention groups in a study, which meant
that including all comparisons separately would result in some
participants being included in the analysis more than once, we
combined the groups to create a single pair-wise comparison as
outlined in Chapter 16 of the Cochrane Handbook for Systematic
Reviews of Interventions (Higgins 2011).
We calculated odds ratios for the dichotomous outcomes of clinical
and mycological cure. In all trials, women were randomised to
treatment group (by the investigators) on the basis of their clinical
symptoms. At the point of randomisation, a swab was taken for
mycological culture. Following randomisation some participants
were excluded because they tested negative for candida. To have
used the number of participants randomised as the denominator
would have underestimated the eDicacy of the individual anti-
fungals. Therefore, the denominator used was the number of
randomised participants who were culture-positive for yeast prior
to receiving an anti-fungal.
We calculated odds ratios for side eDects using the number of
participants reporting side eDects reported in the studies.
The relative safety of both routes of administration was assessed
using the number of withdrawals due to adverse drug reactions.
We calculated this outcome by assessing whether there were any
withdrawals reported in the trials (yes, no, or not reported).
Treatment preference was assessed by recording the number of
people that preferred oral treatment versus the number of people
that preferred intra-vaginal treatment (and the number of people
that had no preference, where relevant) for each study. We then
summed the number of trials that found that overall oral treatment
was preferred, intra-vaginal was preferred, and no preference.
There was variation in how time to first relief of symptoms was
reported in the trials (e.g. mean time, median time, proportion of
patients who experienced relief at specific time points), therefore
the data could not be combined. We recorded in an additional table
the findings from each study that assessed this outcome.
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Unit of analysis issues
All the included studies were randomised controlled trials with a
parallel design. The participants were individually allocated to the
treatment or control groups. There were no cross-over or cluster-
randomised trials and no unit of analysis issues. We included the
per protocol results in the meta-analysis.
Dealing with missing data
There were little missing data. Where trials had limited or unclear
data for an outcome, they were included in the narrative synthesis
of results but excluded from meta-analysis.
Assessment of heterogeneity
We assessed heterogeneity using the I2 statistic, quantifying the
percentage of the total variation across studies that is due to
heterogeneity rather than chance; smaller percentages suggest less
observed heterogeneity (Deeks 2011).
Assessment of reporting biases
We used funnel plots to assess the likelihood of publication bias.
Data synthesis
We used the fixed-eDect Mantel-Haenszel analysis method to
combine outcome data from the trials. Studies that did not
have clear numerators or denominators for an outcome were not
included in the meta-analysis for that outcome. We provide a
descriptive synthesis where data were reported in a form that could
not be entered into meta-analysis.
We analysed individual drug comparisons when there were
suDicient trials to do so. Comparisons included fluconazole versus
clotrimazole, itraconazole versus clotrimazole, fluconazole versus
miconazole, fluconazole versus econazole, itraconazole versus
econazole, fluconazole versus butoconazole, fluconazole versus
fenticonazole, fluconazole versus terconazole, and fluconazole
versus sertaconazole. Single-dose anti-fungal regimens were
compared as well as single- versus multiple-dose treatment.
Subgroup analysis and investigation of heterogeneity
We performed several subgroup analyses.
Sensitivity analysis
Sensitivity analyses were also performed using the methodological
quality criteria (see above) and are described in the text. For the
sensitivity analyses, methodological quality was assessed using the
following criteria and incorporated into the analyses for selection
bias, blinding of the outcome assessor and incomplete outcome
data.
Selection bias included the assessment for both random allocation
and allocation concealment. Random allocation of treatment was
considered as "done" if a random process was used (e.g. random
numbers), or if the authors stated explicitly that the trial groups
were generated by random allocation. Allocation concealment was
"done" if the unit of randomisation was by patient or episode of
care, and some form of centralised randomisation scheme was
used (e.g. sealed opaque envelopes). In order for selection bias
to be considered low risk, both random allocation and allocation
concealment had to be considered as done. If these criteria were
not met, then the study was removed and the analysis repeated
only including those studies that met the criteria for selection bias.
Blinding of the outcome assessor was considered "done" if
outcome assessors were blinded to participants' assignment
status; this was regarded as "done" if the authors stated explicitly
that the outcome measures were assessed blindly. If the criteria
were not met, then the study was removed and the analysis
repeated only including those studies that met the criteria for
blinded outcome assessor.
Incomplete outcome data was considered "done" if follow-up in
the study at the longest time point was 90% or greater. If the
criteria were not met, then the study was removed and the analysis
repeated only including those studies that met the criteria for
incomplete outcome data.
Summary of findings
We graded our confidence in the evidence and summarised the
findings in a 'Summary of findings' table using the approach
recommended by the GRADE (Grades of Recommendation,
Assessment, Development and Evaluation) Working Group (Guyatt
2008). We compared the eDectiveness of oral versus intra-vaginal
anti-fungals for the treatment of uncomplicated vulvovaginal
candidiasis for each of the following important outcomes: clinical
cure, mycological cure, safety, side eDects, treatment preference,
time to first relief of symptoms and costs. We used the five
GRADE considerations (study limitations, consistency of eDect,
imprecision, indirectness, and risk of bias) to assess the certainty
of the evidence as it relates the outcomes (Guyatt 2008). We
used methods and recommendations described in Section 8.5 and
Chapter 12 of the Cochrane Handbook for Systematic Reviews of
Interventions (Higgins 2011).
R E S U L T S
Description of studies
See: Characteristics of included studies
Results of the search
For this update, we retrieved 792 records from database and
registry searches, of which 758 were ineligible. We obtained full-
text articles for the remaining 34 records, seven of which fulfilled
the inclusion criteria for this review (ACCELERATE 2002; Coric 2006;
Murina 2012; Roongpisuthipong 2010; Sanam 2009; Sekhavat 2011;
Škerk V 2006). The total number of trials included in this review is
26 (Figure 1). We identified two systematic reviews to handsearch
(Matheson 2017, van Schalkwyk 2016).
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Figure 1.   Study flow diagram.
 
Included studies
Study design and population
We included 26 randomised controlled trials involving 5007 women
between the ages of 16 and 65 (where reported). Four trials did
not report age of the participants (Boag 1991, Coric 2006, Goode
1992, Mendling 2004). One trial stated an age range of 15 to
50 years, however only eight of 188 participants were under 16
years (Roongpisuthipong 2010). One trial presented median age for
participants by trial group (26 years in one treatment group and 25
years in the other) (Murina 2012).
All of the included studies confirmed the clinical diagnosis of
vaginal candidiasis using mycological culture or microscopy, or
both. Two trials used microscopy only to provide mycological
confirmation of the diagnosis (Slavin 1992; Woolley 1995. There
was variation amongst the remaining trials regarding the definition
used to confirm the mycological diagnosis. Some trials reported
positive "yeast culture" (Boag 1991, Mendling 2004, Osser 1991,
Timonen 1992b, Timonen 1992a), whilst others reported positive
quote: "culture of Candida species" (Adetoro 1990, Andersen 1989,
Mikamo 1995, Mikamo 1995, O-Prasertsawat 1995, Sobel 1995,
Stein 1991, Stein 1993, Tobin 1992, Van Heusden 1990, Van Heusden
1994, Woolley 1995). Two trials reported mycological confirmation
of "Candidiasis" but did not mention a specific species (Goode
1992, Seidman 2005), and one trial reported quote: "positive 10%
KOH preparation for budding yeast and/or pseudohypha" (KOH =
potassium hydroxide) (ACCELERATE 2002). The Seidman 2005 trial
did not perform yeast cultures. In only one study (Adetoro 1990),
was mycological cure defined as the absence of Candida albicans.
The terminology most oMen used in reporting mycological cure was
the absence of growth of Candida species.
Twenty-three trials included women with acute vulvovaginal
candidiasis; three trials included participants with chronic
vulvovaginal candidiasis (Osser 1991, Sobel 1995, Timonen 1992b).
In one of these three trials, the results for clinical cure and
mycological cure for acute vulvovaginal candidiasis were presented
separately from participants with chronic infection, therefore, the
results for this trial were generated from the acute participants
only for these outcomes (Sobel 1995). Of the 258 participants
randomised in the trial by Osser and colleagues, 33 (13%) had
chronic vulvovaginal candidiasis (Osser 1991, and in the trial by
Timonen and colleagues,13 (16%) of the participants had chronic
yeast infections. The duration of follow-up varied between trials
(see additional Table 1). For the purpose of this review, the
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outcome measures that were presented at between five and 15
days were included in the short-term follow-up comparisons, and
the outcome measures that were presented at between two and
12 weeks were included in the long-term follow-up comparisons.
Outcome measures that were presented at time points outside
these follow-up periods were excluded. There is slight overlap
between the duration of short- and long-term follow-up as a result
of the trial by Timonen (Timonen 1992b). Ethnicity of the trial
populations was not reported in any trial. The trials were published
between 1989 (Andersen 1989) and 2012 (Murina 2012).
Setting
Thirteen trials were conducted in Europe: three in the UK (Boag
1991; Tobin 1992; Woolley 1995); two in Croatia (Coric 2006,
Škerk V 2006), Finland (Timonen 1992a; Timonen 1992b) and
the Netherlands (Van Heusden 1990 Van Heusden 1994); one
each in Germany (Mendling 2004), Italy (Murina 2012), Sweden
(Osser 1991); and one trial was conducted across multiple
European countries (Andersen 1989). Additionally, seven studies
were conducted in the USA, (ACCELERATE 2002,Goode 1992,
Seidman 2005, Slavin 1992, Sobel 1995, Stein 1991, Stein 1993);
one in Japan (Mikamo 1995); two each in Thailand (O-Prasertsawat
1995, Roongpisuthipong 2010), Iran (Sanam 2009, Sekhavat 2011);
and one in Africa/Nigeria (Adetoro 1990). Trials were conducted at
both single (n = 10) and multi-centred sites (n = 11) and five trials
did not specify the setting, or were unclear.
Intervention
In total, eight anti-fungals were represented: two oral treatments;
fluconazole and itraconazole,and six intra-vaginal treatments;
butoconazole, clotrimazole, econazole, miconazole, sertaconazole
and terconazole. Fluconazole was compared with clotrimazole
in 15 trials (17 comparisons) (Adetoro 1990; Andersen 1989;
Boag 1991;Coric 2006; Goode 1992; Mendling 2004 (two
comparisons); Mikamo 1995 (two comparisons); O-Prasertsawat
1995; Roongpisuthipong 2010; Sekhavat 2011; Škerk V 2006; Sobel
1995; Stein 1991;Van Heusden 1994; Woolley 1995); miconazole
in three trials (ACCELERATE 2002; Timonen 1992a; Van Heusden
1990), and terconazole (Slavin 1992), econazole (Osser 1991),
butoconazole (Seidman 2005), sertaconazole Roongpisuthipong
2010 and fenticonazole (Murina 2012) in one trial each. Itraconazole
was compared with clotrimazole in four trials (Sanam 2009;
Stein 1993; Tobin 1992; Woolley 1995; and econazole in one trial
(Timonen 1992b).
Outcomes
Thirteen studies reported clinical cure (short term): Coric 2006;
Goode 1992; Murina 2012; Osser 1991; Sanam 2009; Seidman 2005;
Sekhavat 2011; Sobel 1995; Stein 1991; Stein 1993; Timonen 1992b;
Van Heusden 1990; Woolley 1995.
Nine studies reported clinical cure (long term): Goode 1992; Murina
2012; Osser 1991; Škerk V 2006; Sobel 1995; Stein 1991; Stein 1993;
Timonen 1992b; Van Heusden 1990.
Twenty studies reported mycological cure (short term): Adetoro
1990; Andersen 1989; Boag 1991; Coric 2006; Goode 1992;
Mendling 2004; Mikamo 1995; O-Prasertsawat 1995; Osser 1991;
Roongpisuthipong 2010; Sanam 2009; Sekhavat 2011; Sobel 1995;
Stein 1991; Stein 1993; Timonen 1992a; Timonen 1992b; Tobin 1992;
Van Heusden 1990; Woolley 1995.
FiMeen studies reported mycological cure (long term): Adetoro
1990; Andersen 1989; Goode 1992; Mendling 2004; Mikamo 1995;
O-Prasertsawat 1995; Osser 1991; Roongpisuthipong 2010; Sobel
1995; Stein 1991; Stein 1993; Timonen 1992a; Timonen 1992b; Tobin
1992; Van Heusden 1990.
Twenty-three studies reported safety: ACCELERATE 2002; Adetoro
1990; Andersen 1989; Goode 1992; Mendling 2004; Mikamo 1995;
Murina 2012; O-Prasertsawat 1995; Osser 1991; Roongpisuthipong
2010; Sanam 2009; Seidman 2005; Sekhavat 2011; Škerk V 2006;
Slavin 1992; Sobel 1995; Stein 1991; Stein 1993; Timonen 1992a;
Timonen 1992b; Tobin 1992; Van Heusden 1990; Van Heusden 1994
Twenty-two studies reported side eDects: ACCELERATE 2002;
Adetoro 1990; Andersen 1989; Goode 1992; Mendling 2004;
Mikamo 1995; Murina 2012; O-Prasertsawat 1995; Osser 1991;
Roongpisuthipong 2010; Sanam 2009; Seidman 2005; Sekhavat
2011; Škerk V 2006; Slavin 1992; Sobel 1995; Stein 1993; Stein 1991;
Timonen 1992a;Timonen 1992b; Van Heusden 1990; Van Heusden
1994.
Twelve studies reported treatment preference: Adetoro 1990;
Andersen 1989; Coric 2006; Osser 1991; Sekhavat 2011; Slavin
1992; Stein 1993; Timonen 1992b; Timonen 1992a; Tobin 1992; Van
Heusden 1990; Van Heusden 1994.
Ten studies reported time to first relief: ACCELERATE 2002; Adetoro
1990; Andersen 1989; Coric 2006; Mendling 2004; Murina 2012;
Seidman 2005; Slavin 1992; Timonen 1992a; Tobin 1992.
No studies reported on cost.
Compliance and sources of support
Compliance checks were undertaken in seven trials (ACCELERATE
2002; Boag 1991; O-Prasertsawat 1995; Osser 1991; Seidman 2005;
Slavin 1992; Sobel 1995). One trial reported 99.3% compliance
(ACCELERATE 2002), and one did not report the rate or the
numbers of compliance (O-Prasertsawat 1995). The remainder
of these trials reported 100% of participants complied with
treatment. Pharmaceutical industry support was reported in 10
trials (ACCELERATE 2002; Adetoro 1990; Andersen 1989; Osser
1991; Roongpisuthipong 2010; Sobel 1995; Stein 1991; Stein 1993;
Timonen 1992b; Tobin 1992). We were unable to determine industry
support for one trial (Škerk V 2006).
Excluded studies
We excluded 27 articles at full-text review. Twenty-three of these
clearly did not meet the eligibility criteria and were excluded. Four
of these studies appeared to meet the eligibility criteria, but while
conducting data extraction, we determined that they were not
eligible and were subsequently excluded (EUCTR2005-001360-31-
IT; Fan 2015; Li 2015; Zhou 2016). We have provided an explanation
for their exclusion in the Characteristics of excluded studies table
along with the five studies excluded in the last published version of
the review (Nurbhai 2007).
Risk of bias in included studies
See: Characteristics of included studies
The risk of bias tables are presented in Figure 2 and Figure 3.
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Figure 2.   'Risk of bias' summary: reviewers judgements about each risk of bias domain for each included study.









































































































































































































































































































































ACCELERATE 2002 + - - - ? ? ? ? - + + +
Adetoro 1990 + ? - - + + - - - + ? +
Andersen 1989 + - - - + + - - - - ? +
Boag 1991 ? ? - - + + - - - + ? ?
Coric 2006 ? ? - - + + - - - + ? ?
Goode 1992 ? ? - - + ? - - - + ? ?
Mendling 2004 ? ? - - + + - - - - ? ?
Mikamo 1995 ? ? - - + + - - - ? ? +
Murina 2012 ? ? - - ? ? - - - + ? +
O-Prasertsawat 1995 + + - - + + - - - + ? +
Osser 1991 ? ? - - + + - - - + ? +
Roongpisuthipong 2010 + ? - ? + + ? ? - + ? +
Sanam 2009 ? ? - - + + - - - + ? +
Seidman 2005 + ? - - ? ? - - - ? ? +
Sekhavat 2011 ? ? - - + + - - - + ? +
Škerk V 2006 ? ? - ? ? ? ? ? ? ? ? ?
Slavin 1992 + - - - + + - - - + ? -
Sobel 1995 ? ? - - + + - - - + ? +
Stein 1991 + ? - - + + - - - + ? +
Stein 1993 ? ? - - + + - - - - ? +
Timonen 1992a ? ? - - + + - - - ? ? +
Timonen 1992b ? ? + - + + - - - ? ? +
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Figure 2.   (Continued)
Timonen 1992a ? ? - - + + - - - ? ? +
Timonen 1992b ? ? + - + + - - - ? ? +
Tobin 1992 ? ? - - + + - - - - ? ?
Van Heusden 1990 ? ? + - + + - - - + ? +
Van Heusden 1994 + ? - - + + - - - + ? ?
Woolley 1995 ? ? - - + + - - - + ? +
 
 
Figure 3.   'Risk of bias' graph: reviewers judgements about each risk of bias domain presented as percentages
across all included studies. White spaces in the figure represent outcomes that were not reported/assessed.
Random sequence generation (selection bias)
Allocation concealment (selection bias)
Blinding of participants and personnel (performance bias): All outcomes
Blinding of outcome assessment (detection bias): Time to First Relief
Blinding of outcome assessment (detection bias): Mycological Cure
Blinding of outcome assessment (detection bias): Mycological Improvement
Blinding of outcome assessment (detection bias): Clinical Cure
Blinding of outcome assessment (detection bias): Clinical Improvement
Blinding of outcome assessment (detection bias): Side Effects
Incomplete outcome data (attrition bias): All outcomes
Selective reporting (reporting bias)
Other bias
0% 25% 50% 75% 100%
Low risk of bias Unclear risk of bias High risk of bias
 
Allocation
Random sequence generation was adequately described in nine
trials (ACCELERATE 2002; Adetoro 1990; Andersen 1989; O-
Prasertsawat 1995; Roongpisuthipong 2010; Seidman 2005; Slavin
1992; Stein 1991; Van Heusden 1994), and allocation concealment
was conducted appropriately in one (O-Prasertsawat 1995). Three
trials were at high risk for allocation concealment (ACCELERATE
2002; Andersen 1989; Slavin 1992).
Blinding
Blinding of participants was graded as high risk for all trials except
Timonen 1992b and Van Heusden 1990, as participants would be
aware whether they were getting oral or vaginal interventions. For
clinical outcomes, blinding was reported as high risk as the patients
could influence the findings by biased reporting. Mycological
outcomes were reported as low risk because these were derived
from objective tests and not influenced by the patient or assessor.
Blinding participants would be diDicult unless women receiving
active intra-vaginal treatment also received an oral placebo and
vice versa, with the latter being more problematic.
Incomplete outcome data
Four trials were at high risk for incomplete outcome data (Andersen
1989; Mendling 2004; Stein 1993; Tobin 1992). In one trial, attrition
was greater than 10% at the second follow-up (27 to 62 days)
(Andersen 1989). In the second trial, over 25% was lost to follow-up
in all groups with no explanation provided, though the intention-to-
treat data were reported (Mendling 2004). The third trial lost 36.8%
of the total number of participants at the second follow-up at four
weeks (Stein 1993). Twenty per cent were lost to follow-up in the
fourth trial (Tobin 1992).
Selective reporting
No trials were classified as high risk for selective outcome reporting.
Other potential sources of bias
Eighteen trials had a low risk of other potential sources of bias and
seven had an unclear risk. One trial was categorised as high risk
due to baseline imbalances and participants' history of infections
(Slavin 1992).
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E;ects of interventions
See: Summary of findings 1 Oral versus intra-vaginal antifungal
treatment of uncomplicated vulvovaginal candidiasis
See: Summary of findings 1 for the main comparison.
1 Oral versus intra-vaginal antifungal treatment of
uncomplicated vulvovaginal candidiasis
Clinical cure
Fourteen trials reported this outcome. Short-term clinical cure (five
to 15 days) was evaluated in 13 trials (Analysis 1.1); and long-term
clinical cure (two to 12 weeks) was evaluated in nine trials (Analysis
1.2). There was little or no diDerence between oral and intra-vaginal
anti-fungals for clinical cure at either time point; short term (0dds
ratio (OR) 1.14, 95% confidence interval (CI) 0.91 to 1.43; 13 trials;
1859 participants) and long term (OR 1.07, 95% CI 0.77 to 1.50;
9 trials; 1042 participants). We downgraded the certainty of the
evidence for these outcomes to moderate due to serious concern
for risk of bias due to lack of blinding of participants and outcome
assessors.
The evidence suggests that if the rate of clinical cure at short-term
follow-up with intra-vaginal treatment is 77%, the rate with oral
treatment would be between 75% and 83%; if the rate of clinical
cure at long-term follow-up with intra-vaginal treatment is 84%, the
rate with oral treatment would be between 80% and 89%.
There was also little or no diDerence between interventions for any
of the subgroup analyses (see subgroups in the data and analysis
tables (Analysis 1.1; Analysis 1.2)
One trial, (ACCELERATE 2002) was not included in the single dose
versus single dose analyses because, although the participants in
the intra-vaginal group were given a single dose of miconazole, they
were also provided with miconazole nitrate (2%) external vulvar
cream to be applied up to twice daily to the vulvar area.
Three studies compared a single dose of oral therapy versus six to
seven days intra-vaginal therapy on clinical cure. All three studies
had data for short-term follow-up, and the meta-analysis indicated
single dose oral therapy probably achieves slightly better clinical
cure than six to seven days intra-vaginal therapy (OR 1.57, 95% CI
1.03 to 2.42; 427 participants) (Analysis 5.1). Two of these studies
had data for long-term follow-up and this eDect was not seen in
the meta-analysis (OR 0.99, 95% CI 0.54 to 1.83; 266 participants)
(Analysis 5.2). No studies compared single-dose oral therapy versus
three-day intra-vaginal therapy on clinical cure.
Mycological cure
Twenty trials reported short-term mycological cure (Analysis
1.3) and 15 reported long-term mycological cure (Analysis 1.4).
Mycological cure was probably improved with oral anti-fungals
compared with intra-vaginal anti-fungals; short-term follow-up (OR
1.24, 95% CI 1.03 to 1.50; 19 trials; 3057 participants) and at
long-term follow-up (OR 1.29, 95% CI 1.05 to 1.60, 13 trials; 1661
participants). We downgraded the certainty of the evidence to
moderate due to imprecision of the confidence intervals.
The evidence suggests that if the rate of mycological cure at
short -term follow-up with intra-vaginal treatment is 80%, the
rate with oral treatment would be between 80% and 85%; if the
rate of mycological cure at long-term follow-up with intra-vaginal
treatment is 66%, the rate with oral treatment would be between
67% and 76%.
We excluded two trials from the meta-analysis. One trial reported
long-term mycological response using percentages and we were
unable to convert the data to raw numbers (Mendling 2004). We also
excluded a second trial due to lack of clarity regarding numbers and
definition of cure (Roongpisuthipong 2010).
The clinical significance of this finding is uncertain given that
Candida albicans is found routinely in asymptomatic women.
One subgroup analysis (Analysis 1.3.5) (derived from one trial)
showed a diDerence with short-term mycological cure favouring
itraconazole compared with econazole (OR 3.55, 95% CI 1.29
to 9.77; 75 participants). Two subgroup analyses showed a
diDerence with long-term mycological cure, both of which favoured
fluconazole. The first of these analyses (Analysis 1.4.1) comprised
seven trials of fluconazole compared with clotrimazole (OR 1.31,
95% CI 1.00 to 1.71; 1015 participants), and the second analysis
(Analysis 1.4.4) compared fluconazole with econazole (OR 2.17, 95%
CI 1.06 to 4.42; 177 participants).
There was little or no diDerence between oral and intra-vaginal anti-
fungals administered as single-dose treatments on mycological
cure (single-dose oral anti-fungal therapy versus single -dose intra-
vaginal anti-fungal therapy (Analysis 4.3); single-dose oral therapy
versus three-day intra-vaginal therapy (Analysis 3.1, Analysis 3.2);
single-dose oral therapy versus six- to seven-day intra-vaginal
therapy (Analysis 5.3, Analysis 5.4).
Safety
Withdrawal due to adverse drug eDects was used as a measure
of anti-fungal safety. Data from 23 trials (4637 participants) were
included in the assessment of this outcome, either because they
specifically reported on withdrawals due to adverse events, or they
reported data which indicated there were either no side eDects
or minor side eDects only (no adverse events). Of these 23 trials,
three reported withdrawals (Analysis 1.5). One trial reported that
one participant discontinued the miconazole treatment because
of a severe burning sensation in the vagina (Timonen 1992a); a
second trial reported one withdrawal from fluconazole due to
diarrhoea (Stein 1991), and a third trial reported a withdrawal
from the miconazole group due to severe vulvovaginal burning
(ACCELERATE 2002). No withdrawals due to adverse drug reactions
were reported in any other trial. We did not downgrade the certainty
of the evidence as we did not have any major concerns for each
quality domain. Given that the overall number of withdrawals were
low, there was low risk of withdrawal due to adverse drug eDects
for either treatment.
Side eects
Twenty-two trials (4423 participants) evaluated side eDects
(ACCELERATE 2002; Adetoro 1990; Andersen 1989; Goode 1992;
Mendling 2004; Mikamo 1995; Murina 2012; O-Prasertsawat 1995; ,
Roongpisuthipong 2010; Sanam 2009; Seidman 2005; Sekhavat
2011; Škerk V 2006; Slavin 1992; Sobel 1995; Stein 1993; Stein
1991; Timonen 1992a;Timonen 1992b; Van Heusden 1990; Van
Heusden 1994). We were unable to include six trials in the meta-
analysis. Two trials did not provide numerical data about side-
eDect events, indicating that side eDects were minimal (Goode
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1992; Roongpisuthipong 2010). A further three trials reported no
side eDects events for either treatment group, so these trials were
not included in the meta-analysis as they did not provide any
indication of the direction or magnitude of the relative treatment
eDect (Mikamo 1995; Škerk V 2006;Slavin 1992). Lastly, Van Heusden
1994 was not included in the estimates because a denominator was
unclear.
It is undetermined whether oral treatments reduced the number of
side eDects compared with intra-vaginal treatments (OR 1.04, 95%
CI 0.84 to 1.29; 16 trials; 3155 participants; low-certainty evidence).
The evidence suggests that if the rate of side eDects with intra-
vaginal treatment is 12%, the rate with oral treatment would be
between 10% and 15%.
Anti-fungals administered intra-vaginally were more oMen
associated with local reactions (e.g. irritation, "burning", pruritus)
than with those administered by the oral route, but systemic eDects
were also reported (i.e. headache). The oral route of administration
was associated with a wide range of systemic eDects including
gastro-intestinal side eDects and headache.
We downgraded the certainty of the evidence to low due to high risk
of bias and substantial heterogeneity across and within subgroups.
The outcome was self-reported, and trials used diDerent thresholds
for side eDects, i.e. some reported all adverse events occurring
during the evaluation period and some reported only adverse
events that were specifically related to the treatment.
Due to the certainty of evidence being low, we are uncertain
whether oral treatments reduced the number of side eDects
compared with intra-vaginal treatments (Analysis 1.6, Analysis 2.5,
Analysis 5.5).
Treatment preference
Twelve trials (2206 participants) reported a preference for the
route of anti-fungal administration (Adetoro 1990; Andersen 1989;
Coric 2006; Osser 1991; Sekhavat 2011; Slavin 1992; Stein 1993;
Timonen 1992b; Timonen 1992a; Tobin 1992; Van Heusden 1990;
Van Heusden 1994) (Analysis 1.7). These data were poorly reported.
Two trials made statements about treatment preference but no
quantitative data were presented (Adetoro 1990; Stein 1993). The
inconsistencies associated with reporting the preferred route of
administration limit the use of these data. Almost all trials that
reported patient preference favoured oral treatment (compared
with intra-vaginal or no preference), with proportions ranging from
52% of women favouring oral treatment in the trial by Van Heusden
(Van Heusden 1994), to 93% in the Timonen trial (Timonen 1992a).
The trial by Tobin 1992 provided data on whether participants
preferred the study treatment to previous treatments received,
with a higher proportion of the oral treatment group responding
aDirmatively compared to the intra-vaginal treatment group,
however it was not reported whether previous treatments were oral
or vaginal. We downgraded the certainty of the evidence to low due
to the high risk of bias shown in the trials and inconsistencies with
reporting the preferred route of administration.
Time to first relief of symptoms
Ten trials (1910 participants) evaluated time to first relief
(ACCELERATE 2002; Adetoro 1990; Andersen 1989; Coric 2006,
Mendling 2004; Murina 2012; Seidman 2005; Slavin 1992; Timonen
1992a; Tobin 1992). There was little or no diDerence in time to
first relief of symptoms between oral and intra-vaginal treatments.
Four trials favoured the oral treatment, four favoured intra-vaginal,
one study reported no diDerence and one was unclear. There
was considerable variation in the methods used to derive this
outcome and as such, no direct comparisons can be made (Analysis
1.8). There was also variation in the way the data were reported.
For example, five trials reported the median time to first relief
(ACCELERATE 2002; Andersen 1989; Mendling 2004; Seidman 2005;
Slavin 1992), three trials reported the mean time to first relief
(Murina 2012; Slavin 1992; Tobin 1992), and four trials reported
the proportion of patients reporting initial relief at certain time
points (e.g. 12 hours, 24 hours) (ACCELERATE 2002; Coric 2006;
Seidman 2005; Timonen 1992a). No specific data were reported for
this outcome by Adetoro 1990. We downgraded the certainty of the
evidence to low due to high risk of bias for blinding and imprecision
due to self-report.
Cost
None of the included trials reported cost or economic data. No
trial reported the relative cost-eDectiveness of the two modes of
treatment (oral and intra-vaginal).
Sensitivity Analyses
Sensitivity analyses are reported in Table 2. Four main outcomes
were considered; short- and long-term clinical cure and short- and
long-term mycological cure. In all of the analyses for selection bias
or blinded outcome assessor, there were either no comparisons or
one comparison which made any comparison to the full sample of
studies diDicult.
In the analyses for incomplete outcome data, there was a suDicient
number of studies classified as low risk of bias to compare to the
whole sample for the four outcomes. All four of the sensitivity
analyses had odds ratios that fell within the confidence intervals
of the odds ratios for the same outcome including all the studies,
suggesting that the diDerence between the odds ratio for the




Based on our searches of trial registers, we did not identify any
relevant and completed trials that remained unpublished. Through
the database searches, we found one trial that was published as a
conference abstract only. This trial looked at secondary outcomes
of safety, side eDects, and time to first relief (ACCELERATE 2002). We
were able to obtain the full details of the trial from the author and
the manufacturer. The funnel plots were fairly symmetrical (Figure
4; Figure 5; Figure 6; Figure 7; Figure 8).
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Figure 4.   Funnel plot of comparison: 1 Oral vs Intra-vaginal, outcome: 1.1 Clinical cure (short term).
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Figure 5.   Funnel plot of comparison: 1 Oral vs Intra-vaginal, outcome: 1.2 Clinical cure (long term).
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Figure 6.   Funnel plot of comparison: 1 Oral vs Intra-vaginal, outcome: 1.3 Mycological cure (short term).
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Figure 7.   Funnel plot of comparison: 1 Oral vs Intra-vaginal, outcome: 1.4 Mycological cure (long term).
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Figure 8.   Funnel plot of comparison: 1 Oral vs Intra-vaginal, outcome: 1.6 Side e;ects.

















D I S C U S S I O N
Summary of main results
This review compared the relative eDectiveness and
safety of oral versus intra-vaginal anti-fungals for the
treatment of uncomplicated vulvovaginal candidiasis. We
identified 26 trials published between 1989 and 2012 that
examined the eDectiveness of eight anti-fungals: two oral
treatments (fluconazole and itraconazole), and six intra-vaginal
treatments (butoconazole, clotrimazole, econazole, miconazole,
sertaconazole and terconazole).
There was probably little or no diDerence between oral and intra-
vaginal antifungals for short- and long-term clinical cure. Both
routes of administration achieved clinical cure in over 70% of
participants. Similar proportions were observed with short-term
mycological cure. Our confidence in the evidence is moderate, and
this research provides a good indication of the likely eDect.
Six trials reported compliance checks. It is possible that non-
compliance could have contributed to therapeutic failure (clinical
and/or mycological) with some participants.
It is possible that the proportion of women who did not experience
clinical cure following anti-fungal therapy (approximately 20% of
participants participating in the trials included in this review), had
vaginitis due to other causes. Most trials excluded participants with
concomitant vaginal infections (e.g. chlamydia, Trichomonas). It is
possible that some participants may have had an undiagnosed
urogenital infection or condition which, in addition to their
fungal infection, contributed to their clinical symptoms. Other
factors may have influenced unresponsive women's symptoms,
including chemical irritants (e.g. perfumed products, detergents)
and physical damage (e.g. due to tampons, sexual intercourse).
Oral treatment probably improves mycological cure in the short-
and long-term follow-up over intra-vaginal treatment. While our
confidence in the evidence is moderate, and this research provides
a good indication of the likely eDect, the short-term cure rate of
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83% and 80% for oral and intra-vaginal preparations, respectively,
requires consideration, i.e. what were the causes of therapeutic
failure in approximately 20% of women treated? Therapeutic failure
may have been due to the presence of fungal species outside
the spectrum of the anti-fungals used, or, resistance to specific
anti-fungals. The prevalence of non-albicans species has increased
rapidly in recent years (Spinillo 1997). Non-albicans Candida
species are associated with vaginitis but these organisms are more
resistant to conventional anti-fungal therapy (Sobel 1993). There is
evidence that C. glabrata and C. krusei are resistant to fluconazole
and itraconazole (Rex 2000).
The decrease in mycological cure at long-term follow-up may be
explained to some extent by the re-growth of normal Candida
species as part of the vaginal flora. The higher long-term clinical
cure rates support this theory (i.e. the number of women who
were mycologically cured decreased between short- and long-
term follow-up, however, a corresponding reduction in clinical
cure for these time points was not shown). Other factors may
contribute to the reduction in mycological cure. Women may have
been exposed to risk factors associated with vaginal candidiasis
following their entry into a study. Fluctuations in hormone
balance (e.g. menstruation, contraceptive use), drug use (e.g.
antibiotics, corticosteroids), and changes in hygiene, diet or sexual
behaviour, may result in Candidal colonisation (Reed 1992, Sobel
1993, Anonymous 1999). Undiagnosed diabetes may also be a
contributory factor to recurrent infection (Anonymous 1999).
There was probably little or no diDerence between single-dose oral
anti-fungal treatment and multiple-dose intra-vaginal regimens.
This contrasts with the results of a review of the treatment
of vaginal candidiasis in pregnancy that showed multiple dose
treatment to be more eDective than single-dose anti-fungal therapy
(Young 2001).
Withdrawal due to adverse drug eDects was used as a measure
of anti-fungal safety. There was a low risk of withdrawals due
to adverse drug eDects for either treatment. Three of 22 studies
reported one withdrawal each: two from the intra-vaginal group
and one from the oral treatment group. While having few
withdrawals appears to demonstrate a low risk, we are not sure
which treatment has less risk. The certainty of the evidence was
high.
There was little or no diDerence between treatments in terms of
side eDects. The certainty of the evidence is low and it is possible
that with additional research, the eDects could change. Intuitively,
the oral administration of any drug, anti-fungal or otherwise, is
more likely to be associated with a greater proportion of adverse
drug reactions than the intra-vaginal administration of a drug from
the same therapeutic category. Furthermore, adverse reactions
resulting from anti-fungals given systemically may be more severe
or have more serious consequences than those occurring with
intra-vaginal administration.
Patient treatment preference for route of anti-fungal
administration was assessed as a secondary outcome measure.
Data for this outcome were poorly reported and our confidence
in the evidence is low. The majority of trials which included this
outcome presented percentages of participants who preferred oral
treatment and percentages who preferred intra-vaginal treatment,
but the denominator was oMen not reported, and neither were
data on whether participants had previous experience of oral and/
or intra-vaginal anti-fungal therapy. Despite this shortcoming, the
oral route was consistently the preferred route of administration
for anti-fungals in trials included in this review. It should be
bourne in mind, however, that oral preparations are usually more
expensive than intra-vaginal treatments and the systemic side
eDects associated with oral treatment are likely to be of a more
serious nature than intra-vaginal anti-fungals.
We found that there was little or no diDerence that oral treatments
were faster than intra-vaginal treatments for symptom relief (time
to first relief) as reported by participants. There was considerable
variation in the methods used to derive this outcome and in the way
the data were reported. As the certainty of the evidence is low, it is
possible that with future research this eDect could change.
We were unable to determine the impact of oral versus intra-
vaginal treatment on costs. Few data were present in the included
trials that could be used in a cost-eDectiveness analysis. Generally,
oral anti-fungal treatment is more expensive than intra-vaginal
therapies. Whether it is the woman or her health system who
pays for her anti-fungal treatment will have implications in terms
of the diDerence in costs between the two options for route of
administration.
Overall completeness and applicability of evidence
A variety of anti-fungals are available worldwide for the treatment
of this infection. In some countries, these drugs can be purchased
without a prescription enabling customers to self-medicate. Our
search strategies included all the generic names of identifiable
anti-fungals that are available world-wide and which are licensed
for the treatment of uncomplicated vulvovaginal candidiasis. We
identified 26 trials published between 1989 and 2012 that examined
the eDectiveness of eight anti-fungals (two oral treatments;
fluconazole and itraconazole,and six intra-vaginal treatments;
butoconazole, clotrimazole, econazole, miconazole, sertaconazole
and terconazole). All but three trials included participants with
acute vulvovaginal candidiasis. Trials were conducted mainly
in high-income countries. The duration of follow-up varied
between trials. We were able to identify one unpublished trial
through the searches (ACCELERATE 2002). Despite contacting the
manufacturers of anti-fungal preparations in the UK for the original
review (Nurbhai 2007), we did not locate any others and did not
contact manufacturers for this update. We did not limit the search
strategies to English language publications, reducing the risk of
publication bias (Egger 1997a,Egger 1997b, Moher 1996).
Trials either used a defined range of age limits for their inclusion
criteria, were open ended, or did not specify the ages of the
participants, thus it was diDicult to get a clear picture of the full
range of ages of the participants from the trials. One trial stated
an age range of 15 to 50 years (Roongpisuthipong 2010). While this
age range was outside our pre-specified inclusion criteria (16 years
or over), we included this trial in our analyses because only eight
participants were in the 15 to 19 year age range. Two additional
trials included in our analysis had a lower age limit of 15 years
old in their age criteria, however the participants were all aged 16
years and over ( Adetoro 1990; Osser 1991). Lastly, four trials did
not report the age of participants (Boag 1991, Coric 2006, Goode
1992, Mendling 2004), and one only presented median age for
participants by trial group (26 years in one treatment group and 25
years in the other) (Murina 2012).
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We did not include trials of oral ketoconazole or intra-vaginal
ketoconazole in this review due to previous concerns regarding
its safety profile. This drug is available in some countries for the
treatment of vaginal candidiasis, however, it was not included in
this review. The authors of future updates of this review might wish
to consider the inclusion of trials of intra-vaginal formulations of
ketoconazole.
Quality of the evidence
We identified 26 randomised controlled trials involving 5007
women between the ages of 15 and 65 (where reported). Twenty-
three trials included women with acute vulvovaginal candidiasis
and three trials included women with chronic vulvovaginal
candidiasis. There were eight anti-fungals studied: two oral
treatments and six intra-vaginal treatments.
The certainty of the evidence ranged from low to high. The main
reason for downgrading was due to serious concern with regards
to risk of bias followed by substantial heterogeneity across and
within subgroups. There were inconsistencies associated with
reporting and we were unable to determine precise eDects for some
outcomes.
Overall, the risk of bias of the included trials was high. Allocation
concealment was poorly reported in all but one trial. Outcome
assessment was not blinded in many trials and may have resulted
in performance bias in terms of clinical cure. However, all
women received active treatment which suggests that this should
have been balanced between groups and might not necessarily
represent a form of bias unless there was an interaction between
treatment preference and treatment received. The denominator
could not be calculated for a number of trials because of the poor
reporting of data.
Pharmaceutical industry support was reported in 10 trials.
It is possible that of the remaining trials, some also had
pharmaceutical industry involvement that was not reported.
Pharmaceutical sponsorship may be associated with publication
bias in randomised trials of drug comparisons (Rochon 1994).
Potential biases in the review process
Using the denominator based upon the number of participants
randomised instead of those who were mycologically positive for
yeast altered the findings of the review: no statistically significant
diDerences were shown between oral and intra-vaginal treatments
when this denominator was used. It should be borne in mind
that using the former denominator may overestimate the anti-
fungal eDect because a proportion of women randomised on the
basis of their clinical symptoms will have a negative yeast culture.
Using the number of women who had a positive yeast culture
as the denominator will underestimate the number of women
experiencing clinical cure if recruitment and randomisation has
been performed on the basis of these clinical symptoms.
Agreements and disagreements with other studies or
reviews
A total of 41 RCTs were included in a recent Bayesian network meta-
analysis of the eDicacy of anti-fungal medicines for the treatment of
vaginal candidiasis (Qin 2018). Seven of the antifungals tested were
shown to be more eDective than placebo and of these, fluconazole
was deemed to be most eDective. This study also included studies
of ketoconazole as well as non-azole antifungals, and did not
restrict comparisons to oral versus intra-vaginal.
A U T H O R S '   C O N C L U S I O N S
Implications for practice
There is little or no diDerence between oral and intra-vaginal
anti-fungals in terms of clinical cure. Oral antifungal treatment
achieved slightly higher mycological cure rates than intra-vaginal
administration of these agents. The decision to prescribe or
recommend the purchase of an anti-fungal for oral or intra-vaginal
administration should take into consideration: cost, treatment
preference, and contraindications.
Unless there is a previous history of adverse reaction to one route
of administration or contraindications, women who are purchasing
their own treatment should be given full information about the
characteristics and costs of treatment to make their own decision.
If health services are paying the treatment cost, decision-makers
should weigh up the higher cost of oral anti-fungal administration
with the marginal gain in mycological cure.
Implications for research
It is questionable whether further trials need to be conducted
comparing oral and intra-vaginal anti-fungals. If further trials
are conducted, however, they need to incorporate measures of
methodological quality specified in this review, robust methods
of assessing and reporting treatment preference, and, full
health economic assessments of the treatment options under
investigation. Further trials need to address outcomes that are
useful to the patients for example time to first relief of symptoms
(Seidman 2005), adverse events and patient preferences.
Adequate methods of allocation concealment should be used to
avoid bias (Schulz 1995).
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C H A R A C T E R I S T I C S   O F   S T U D I E S
Characteristics of included studies [ordered by study ID]
 
Study characteristics
Methods Study design: randomised trial (multi-centre)
Follow-up: 91.3% completed study, 82.9% included in efficacy evaluable sample
Participants Age: 18 years or older
Country: USA
Setting: 24 centres (Obstetic/Gyncology OPD)
Diagnosis: vulvovaginal candidiasis by positive 10% potassium hydroxide wet preparation
Characteristics: non-pregnant, non-nursing, with negative wet mount for trichomonas and clue cells
and total vulvovaginal signs/symptoms score of 4 or more.
Enrolled: 310 (305 evaluable)
Interventions Group 1: fluconazole oral 150 mg (single dose (n = 150);
Group 2: miconazole nitrate, 1200 mg vaginal suppository plus external vulvar 2% cream (Monistat©
combination pack) single dose (n = 160)
Duration: 11 April to 23 October 2002
Outcomes Assessed at: 2, 4, 6, 12, 16, 24, 36, 48, 60, and 72 hours following first administration of the MONISTAT
External Cream and/or OVULE Insert, or ingestion of the oral tablet. Follow-up: posttherapy telephone
contact approximately seven to 10 days following.
Efficacy
ACCELERATE 2002 
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Mycological cure: not reported
Mycological improvement: not reported
Clinical cure: not reported
Safety: reported
Quote:"one subject (04506) was withdrawn for a clinically significant adverse event".
Side effects: reported
Drug 1: 17 (11.4%) participants reported at least one treatment-emergent adverse event during the
study
Drug 2: 17 (10.9%) participants reported at least one treatment-emergent adverse event during the
study
Treatment preference: not assessed
Time to first relief: reported.
Time to first relief: (itching, burning, irritation) self-report using diary/worksheet. Based on change in
total symptom scores. Primary efficacy parameter was to be the first recorded time of symptom relief,
defined as the length of time between the first dose of study drug and the time first relief was noted OR
the length of time between the first dose of study drug and the time first relief was noted on the diary.
The time to overall symptom relief was to be based on the maximum time to relief of any of the symp-
toms of itching, burning, or irritation.
Other: change in symptom score from baseline, consumer satisfaction (Consumer Satisfaction Ques-
tionnaire) adverse events (stated - preferred form of therapy)
Costs: not assessed
Notes Compliance check: yes. At the Posttherapy Telephone Contacts (seven to 10 days following the first
dose of study medication), the use of the study medication was confirmed.
A total of 303 (99.3%)participants in the safety population were considered compliant
Pharmaceutical industry support: study sponsored by Personal Products Company
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "randomization sequence provided by Personal Products Company
(PPC)"
Quote: "Eligible subjects were to be equally randomized in strict sequential or-
der to one of two treatment regimens according to a randomization schedule
generated by PPC. There was no blinding in this study."
Allocation concealment
(selection bias)





High risk Quote: "There was no blinding in this study"
Blinding of outcome as-
sessment (detection bias)
High risk Quote: "There was no blinding in this study". Patient self-report.
ACCELERATE 2002  (Continued)
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Time to First Relief
Blinding of outcome as-
sessment (detection bias)
Mycological Cure
Unclear risk Outcome not assessed.
Blinding of outcome as-
sessment (detection bias)
Mycological Improvement
Unclear risk Outcome not assessed.
Blinding of outcome as-
sessment (detection bias)
Clinical Cure
Unclear risk Outcome not assessed.
Blinding of outcome as-
sessment (detection bias)
Clinical Improvement
Unclear risk Outcome not assessed
Blinding of outcome as-
sessment (detection bias)
Side Effects




Low risk Less than 10% lost to follow-up and close in both groups.
Selective reporting (re-
porting bias)
Low risk Protocol available, see section 7.2 in protocol, page 111.





Methods Study design: randomised trial
Follow-up: 100%
Participants Age: 17-30 years old
Country: Africa/Nigeria
Setting: Gynaecological and "special treatment" clinics at the University of Ilorin Teaching Hospital
Diagnosis: mycological culture, positive microscopic smear and clinical symptoms.
Characteristics: non-lactating
Enrolled: 43
Interventions Group 1: fluconazole (oral) 15 0mg single dose (n = 23)
Group 2: clotrimazole 500 mg vaginal tablet single dose (n = 20)
Duration: May 1, 1989 to October 31, 1989
Outcomes Assessed at 8 and 32 days.
Efficacy
Mycological cure: negative culture and negative microscopy
Clinical Improvement: cure or, persistence of C. albicans and absence of symptoms.
Adetoro 1990 
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Safety: no withdrawals due to side effects reported
Side effects: number of side effects reported.
Treatment preference: reported
Time to first relief: assessed, but no specific data reported
Costs: not assessed
Notes Compliance checks: not specified
Pharmaceutical industry support: yes: Pfizer Products Limited
The results do not distinguish between clinical and mycological cure
Actual participant numbers not presented for mycological outcome - only percentage values given.
This trial had a lower age limit of 15 years old in their age criteria, however the participants were all
aged 16 years and over.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Predetermined randomisation code, probably random.
Allocation concealment
(selection bias)





High risk Not possible given nature of intervention.
Blinding of outcome as-
sessment (detection bias)
Time to First Relief
High risk Not possible given nature of intervention, and self-report.
Blinding of outcome as-
sessment (detection bias)
Mycological Cure
Low risk Testing done by lab cultures, which are objective outcomes, not influenced by
blinding.
Blinding of outcome as-
sessment (detection bias)
Mycological Improvement
Low risk Testing done by lab cultures, which are objective outcomes, not influenced by
blinding.
Blinding of outcome as-
sessment (detection bias)
Clinical Cure
High risk Not possible given nature of intervention, and subjective outcome.
Blinding of outcome as-
sessment (detection bias)
Clinical Improvement
High risk Not possible to avoid risk given nature of intervention, and subjective out-
come.
Blinding of outcome as-
sessment (detection bias)
Side Effects





Low risk No losses to follow-up, all participants completed study.
Adetoro 1990  (Continued)
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Selective reporting (re-
porting bias)
Unclear risk No protocol or trial registration described.





Methods Study design: randomised trial (multi-centre)
Follow-up: 82.7%
Participants Age: > 18
Country: Europe (Denmark, Finland, France, Germany, Norway, the Netherlands)
Setting: not specified (16 centres in various European countries)
Diagnosis: mycological culture and microscopy
Characteristics: non-lactating
Enrolled: 372 enrolled: 369 randomised
Interventions Group 1: fluconazole (oral) 150 mg single dose (n = 188)
Group 2: clotrimazole 200 mg vaginal tablets for 3 days. (n = 181)
Duration: not specified
Outcomes Assessed at 5 -16 days and 27-62 days.
Efficacy
Clinical improvement: response/relief from symptoms and elimination of signs of vaginal infec-
tion.Quote: "Favourable" clinical response if cured or improved.
Mycological cure: eradication of Candida (negative culture and microscopy)
Safety: no withdrawals due to side effects reported
Side effects: participant reported side effects.
Treatment preference: reported for one study centre.
Time to first relief: reported - median time to first relief
Costs: not assessed
Notes Compliance checks: not specified
Pharmaceutical industry support: yes - Pfizer Central Research, Sandwich, England
% follow-up calculated based on number randomised
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Computer-generated randomisation list, probably random.
Allocation concealment
(selection bias)




High risk Not possible, given nature of intervention.
Andersen 1989 
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All outcomes
Blinding of outcome as-
sessment (detection bias)
Time to First Relief
High risk Not possible given nature of intervention and symptoms.
Blinding of outcome as-
sessment (detection bias)
Mycological Cure
Low risk Testing done by lab cultures, which are objective outcomes, not influenced by
blinding.
Blinding of outcome as-
sessment (detection bias)
Mycological Improvement
Low risk Testing done by lab cultures, which are objective outcomes, not influenced by
blinding.
Blinding of outcome as-
sessment (detection bias)
Clinical Cure
High risk Not possible to avoid risk given nature of intervention, and subjective out-
come.
Blinding of outcome as-
sessment (detection bias)
Clinical Improvement
High risk Not possible to avoid risk given nature of intervention, and subjective out-
come.
Blinding of outcome as-
sessment (detection bias)
Side Effects









Unclear risk No protocol described.





Methods Study design: randomised trial
Follow-up: 90.9%
Participants Age: not specified
Country: UK
Setting: Genito-urinary medicine clinic (London)
Diagnosis: mycological culture and clinical symptoms
Characteristics: non-lactating
Enrolled: 23 (22 evaluable)
Interventions Group 1: fluconazole (oral) 150 mg single dose (n = 11)
Group 2: clotrimazole 500 mg pessary (single dose) (n = 11)
Duration: not specified
Outcomes Assessed at 2, 4, 6 and 10 days after treatment.
Efficacy
Boag 1991 
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Mycological cure: no yeasts isolated
Clinical cure: not assessed
Safety: not assessed
Side effects: not assessed
Treatment preference: not assessed
Time to first relief: not assessed
Costs: not assessed
Notes Compliance check: done E (nurse-administered) all 22 (100%) patients were compliant with treatment.
Pharmaceutical industry support: not specified
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk No description provided.
Allocation concealment
(selection bias)





High risk Not possible given nature of intervention.
Blinding of outcome as-
sessment (detection bias)
Time to First Relief
High risk Not possible to avoid risk given nature of intervention, and subjective out-
come.
Blinding of outcome as-
sessment (detection bias)
Mycological Cure
Low risk Testing done by lab cultures, which are objective outcomes, not influenced by
blinding.
Blinding of outcome as-
sessment (detection bias)
Mycological Improvement
Low risk Testing done by lab cultures, which are objective outcomes, not influenced by
blinding.
Blinding of outcome as-
sessment (detection bias)
Clinical Cure
High risk Not possible to avoid risk given nature of intervention, and subjective out-
come.
Blinding of outcome as-
sessment (detection bias)
Clinical Improvement
High risk Not possible to avoid risk given nature of intervention, and subjective out-
come.
Blinding of outcome as-
sessment (detection bias)
Side Effects





Low risk Only one of 23 patients lost to follow-up.
Boag 1991  (Continued)
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Selective reporting (re-
porting bias)
Unclear risk No protocol described.





Methods Study design: randomised trial
Follow-up: 100%
Participants Age: not specified
Pregnancy status: not specified
Country: Croatia
Ethnicity: unspecified
Setting: O&G OPD, University of Zagreb
Diagnosis: mycological
Enrolled: 119
Interventions Group 1: fluconazole (oral) (n = 60) 150 mg single dose
Group 2: clotrimazole vaginal tablet 200 mg once daily for 3 days (n = 59)
Duration: September 2004 to July 2005
Outcomes Assessed at 24 hours and 14 days
Efficacy
Mycologocal cure: negative culture
Clinical cure: complete relief of symptoms.
Safety: not assessed
Side effects: not assessed
Treatment preference: reported (oral)
Time to first relief: reported - onset of symptomatic relief in the first 24 hours of treatment
Costs: not assessed
Notes Compliance: not specified
Pharmaceutical industry support: not specified
Risk of bias
Bias Authors' judgement Support for judgement
Coric 2006 
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Random sequence genera-
tion (selection bias)
Unclear risk No description provided.
Allocation concealment
(selection bias)





High risk Not possible given nature of intervention.
Blinding of outcome as-
sessment (detection bias)
Time to First Relief
High risk Not possible to avoid risk given nature of intervention, and subjective out-
come.
Blinding of outcome as-
sessment (detection bias)
Mycological Cure
Low risk Testing done by lab cultures, which are objective outcomes, not influenced by
blinding.
Blinding of outcome as-
sessment (detection bias)
Mycological Improvement
Low risk Testing done by lab cultures, which are objective outcomes, not influenced by
blinding.
Blinding of outcome as-
sessment (detection bias)
Clinical Cure
High risk Not possible to avoid risk given nature of intervention, and subjective out-
come.
Blinding of outcome as-
sessment (detection bias)
Clinical Improvement
High risk Not possible to avoid risk given nature of intervention, and self-report.
Blinding of outcome as-
sessment (detection bias)
Side Effects





Low risk All participants had outcome measures
Selective reporting (re-
porting bias)
Unclear risk No protocol described





Methods Study design: randomised trial
Follow-up: 42.9% (16 of 28 participants were excluded due to negative culture at baseline. All remain-
ing participants were followed up.)
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Characteristics: not specified
Enrolled: n = 28 (12 evaluable)
Interventions Group 1: fluconazole (oral) 150 mg single dose (n = 14)
Group 2: clotrimazole vaginal tablets 100 mg for 7 days.(n = 14)
Duration: seven days (not otherwise specified)
Outcomes Assessed at 2 and 4 weeks.
Efficacy
Clinical cure - complete relief of symptoms
Mycological cure - quote: "mycological efficacy"
Safety: no withdrawals reported
Side effects: specific data not reported
Treatment preference: not assessed/reported
Time to first relief: not assessed
Costs: not assessed
Notes Compliance checks: not specified
Pharmaceutical industry support: not specified
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Not specified.
Allocation concealment
(selection bias)





High risk Not possible given nature of intervention.
Blinding of outcome as-
sessment (detection bias)
Time to First Relief
High risk Not possible to avoid risk given nature of intervention, and self-report.
Blinding of outcome as-
sessment (detection bias)
Mycological Cure
Low risk Testing done by lab cultures, which are objective outcomes, not influenced by
blinding.
Blinding of outcome as-
sessment (detection bias)
Mycological Improvement
Unclear risk Testing done by lab cultures, which are objective outcomes, not influenced by
blinding.
Blinding of outcome as-
sessment (detection bias)
Clinical Cure
High risk Not possible to avoid risk given nature of intervention, and self-report.
Blinding of outcome as-
sessment (detection bias)
High risk Not possible to avoid risk given nature of intervention, and self-report.
Goode 1992  (Continued)
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Clinical Improvement
Blinding of outcome as-
sessment (detection bias)
Side Effects




Low risk High number of dropouts but justified in text.
Selective reporting (re-
porting bias)
Unclear risk No protocol available.





Methods Study design: randomised trial
Follow-up: 472 out of 679 (69.5%) participants were included in the per-protocol population. Reasons
for the exclusions were not provided.
Participants Age: not specified
Country: Germany
Setting: not specified outpatient multi-centre
Diagnosis: visual examination, KOH, mycological culture
Characteristics: not specified
Enrolled: 679 (472 evaluable)
Interventions Group 1: clotrimazole 500 mg vaginal tablet single dose n = 226
Group 2: clotrimazole 10% vaginal cream in a single dose applicator n = 226
Group 3: fluconazole (oral) 15 0mg single dose n = 227
Duration: not specified
Outcomes Assessed at 2, 4 and 8 weeks
Efficacy
Mycological cure: mycological culture results
Clinical cure: unclearly reported
Safety: no withdrawals due to side effects reported
Side effects: reported
Treatment preference: not assessed
Time to first relief: reported - median time to onset of meaningful symptom relief
Costs: not assessed
Notes Compliance checks: not specified
Pharmaceutical industry support: not specified
Risk of bias
Mendling 2004 
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Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk No description provided.
Allocation concealment
(selection bias)





High risk Not possible to avoid risk given nature of intervention.
Blinding of outcome as-
sessment (detection bias)
Time to First Relief
High risk Not possible to avoid risk given nature of intervention, and self-report.
Blinding of outcome as-
sessment (detection bias)
Mycological Cure
Low risk Testing done by lab cultures, which are objective outcomes, not influenced by
blinding.
Blinding of outcome as-
sessment (detection bias)
Mycological Improvement
Low risk Testing done by lab cultures, which are objective outcomes, not influenced by
blinding.
Blinding of outcome as-
sessment (detection bias)
Clinical Cure
High risk Not possible to avoid risk given nature of intervention, and self-report.
Blinding of outcome as-
sessment (detection bias)
Clinical Improvement
High risk Not possible to avoid risk given nature of intervention, and self-report.
Blinding of outcome as-
sessment (detection bias)
Side Effects








Unclear risk No protocol described.





Methods Study design: randomised trial
Follow-up: no description of number of participants lost to follow-up
Participants Age: 18-54
Country: Japan
Setting: O&G OPD (single centre)
Mikamo 1995 
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Diagnosis: mycological culture
Characteristics: non-pregnant and non-lactating
Enrolled: 150
Interventions Group 1: fluconazole (oral) 150 mg single dose (N = 50)
Group 2: clotrimazole (vaginal) 100 mg for 6 days. (N = 50)
Group 3: fluconazole (oral) 50 mg daily for 6 days (n = 50 women)
Outcomes Assessed at 5-15 days and 30-60 days.
Efficacy
Clinical cure - complete disappearance of presenting signs and symptoms
Mycological cure: negative culture and microscopy for Candida species
Safety: no withdrawals due to adverse drug reaction.
Side effects: quote: "No adverse drug effects were noted"
Treatment preference: not assessed
Time to first relief: not assessed
Costs: not assessed
Notes Compliance checks: not specified
Pharmaceutical industry support: not specified
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk No description provided.
Allocation concealment
(selection bias)





High risk Not possible to avoid risk given nature of intervention, and self-report.
Blinding of outcome as-
sessment (detection bias)
Time to First Relief
High risk Not possible to avoid risk given nature of intervention, and self-report.
Blinding of outcome as-
sessment (detection bias)
Mycological Cure
Low risk Testing done by lab cultures, which are objective outcomes, not influenced by
blinding.
Blinding of outcome as-
sessment (detection bias)
Mycological Improvement
Low risk Testing done by lab cultures, which are objective outcomes, not influenced by
blinding.
Blinding of outcome as-
sessment (detection bias)
Clinical Cure
High risk Not possible to avoid risk given nature of intervention, and self-report.
Blinding of outcome as-
sessment (detection bias)
High risk Not possible to avoid risk given nature of intervention, and self-report.
Mikamo 1995  (Continued)
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Clinical Improvement
Blinding of outcome as-
sessment (detection bias)
Side Effects




Unclear risk No description of number of participants lost to follow-up.
Selective reporting (re-
porting bias)
Unclear risk No protocol described.





Methods Study design: randomised trial
Follow-up: 100%
Participants Age: median of 26 years in the oral treatment group and 25 years in the intra-vaginal treatment group
Country: Italy
Setting: not specified
Diagnosis: lab test, reported symptoms
Characteristic: non-pregnant
Enrolled: 80
Interventions Group 1; fluconazole oral 150 mg repeat dose (N = 40)
Group 2: fenticonazole (intra-vaginal) 600 mg (N = 40) repeat dose on day 3
Duration: not specified
Outcomes Assessed at day 7 and 30 +/- 5 days
Efficacy
Mycological cure: bot assessed
Clinical cure: responders
Safety: Reported - quote: “no patient belonging to the two groups had to suspend treatment due to the
presence of severe side effects.”
Side effects: reported - quote: "Three women reported transient nausea after taking fluconazole, while
two patients showed burning sensation short vaginal discharge after insertion vaginal fenticonazole."
Treatment preference: not assessed
Time to first relief: reported mean time to first relief of vulvovaginal pruritus
Costs: not assessed
Murina 2012 
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Notes Compliance checks: not specified
Pharmaceutical industry support: not specified
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk No description provided.
Allocation concealment
(selection bias)





High risk Not possible to avoid risk given nature of intervention.
Blinding of outcome as-
sessment (detection bias)
Time to First Relief
High risk Not possible to avoid risk given nature of intervention, and self-report.
Blinding of outcome as-
sessment (detection bias)
Mycological Cure
Unclear risk Outcome not assessed
Blinding of outcome as-
sessment (detection bias)
Mycological Improvement
Unclear risk Outcome not assessed
Blinding of outcome as-
sessment (detection bias)
Clinical Cure
High risk Not possible to avoid risk given nature of intervention, and self-report.
Blinding of outcome as-
sessment (detection bias)
Clinical Improvement
High risk Not possible to avoid risk given nature of intervention, and self-report.
Blinding of outcome as-
sessment (detection bias)
Side Effects




Low risk All participants had outcome measures.
Selective reporting (re-
porting bias)
Unclear risk No culture data. No protocol described.





Methods Study design: randomised trial
O-Prasertsawat 1995 
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Follow-up: 95.1%
Participants Age: 25-43 years
Country: Thailand (Bangkok)
Setting: Hospital obstetrics and gynaecology out-patient department (single centre)
Diagnosis: visual examination, mycological culture and clinical symptoms
Enrolled: 110 (103 evaluable)
Interventions Group 1: fluconazole (oral)150 mg single dose (n = 53)
Group 2: clotrimazole vaginal tablets 200 mg for 3 days. (n = 50)
Duration: June 1, 1993 to September 30. 1993
Outcomes Assessed at 1 and 4 weeks.
Efficacy
Clinical cure: not reported
Mycological cure - failure to grow Candida species.
Safety: no withdrawals due to side effects reported
Side effects: reported side effects (nausea. dizziness, vaginal burning)
Treatment preference: not reported
Time to first relief: not assessed
Costs:not assessed
Notes Compliance Check: yes - participant questioned regarding use of anti-fungal drugs. No other data re-
ported.
Pharmaceutical industry support: not specified
The denominator for each outcome was based upon the number randomised as the authors did not in-
dicate at what stage the patient withdrawals from the study occurred.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)










High risk Not possible to avoid risk given nature of intervention.
Blinding of outcome as-
sessment (detection bias)
Time to First Relief
High risk Not possible to avoid risk given nature of intervention and self-report.
Blinding of outcome as-
sessment (detection bias)
Mycological Cure
Low risk Testing done by lab cultures, which are objective outcomes, not influenced by
blinding.
O-Prasertsawat 1995  (Continued)
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Blinding of outcome as-
sessment (detection bias)
Mycological Improvement
Low risk Testing done by lab cultures, which are objective outcomes, not influenced by
blinding.
Blinding of outcome as-
sessment (detection bias)
Clinical Cure
High risk Not possible to avoid risk given nature of intervention, and self-report.
Blinding of outcome as-
sessment (detection bias)
Clinical Improvement
High risk Not possible to avoid risk given nature of intervention, and self-report.
Blinding of outcome as-
sessment (detection bias)
Side Effects




Low risk No loss to follow-up
Selective reporting (re-
porting bias)
Unclear risk No protocol described





Methods Study design: randomised trial
Follow-up: 91.1%
Participants Age: 16-60 years old
Country: Sweden
Setting: multi-centre O&G OPD
Diagnosis: Visual examination, KOH, mycological culture, clinical symptoms.
Characteristics: Non-pregnant
Enrolled: 258 (235 evaluable)
Interventions Group 1: Econazole 150mg vaginal depot tablet, single dose. (n = 130) (114 evaluable)
Group 2: Fluconazole (oral) 150mg single dose. (n = 128) (121 evaluable)
Duration: August 1989 to February 1990
Outcomes Measured at 7-10 days, 28-35 days and 80-100 days.
Efficacy
Mycological cure - mycological culture - absence of yeast fungi
Clinical cure. - absence of symptoms
Safety: no withdrawals due to side effects reported
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Time to first relief: not assessed
Costs: not assessed
Notes Compliance check: yes - questioning at 7-10 day follow-up. 235 participants (100%) were compliant
with treatment.
Pharmaceutical industry support: yes - Pfizer AB
19 fluconazole and 14 econazole participants had experienced at least 3 episodes of VVC in the previ-
ous 12 months.
This trial had a lower age limit of 15 years old in their age criteria, however the participants were all
aged 16 years and over.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk No description provided.
Allocation concealment
(selection bias)





High risk Not possible to avoid risk given nature of intervention.
Blinding of outcome as-
sessment (detection bias)
Time to First Relief
High risk Not possible to avoid risk given nature of intervention, and self-report.
Blinding of outcome as-
sessment (detection bias)
Mycological Cure
Low risk Testing done by lab cultures, which are objective outcomes, not influenced by
blinding.
Blinding of outcome as-
sessment (detection bias)
Mycological Improvement
Low risk Testing done by lab cultures, which are objective outcomes, not influenced by
blinding.
Blinding of outcome as-
sessment (detection bias)
Clinical Cure
High risk Not possible to avoid risk given nature of intervention, and self-report.
Blinding of outcome as-
sessment (detection bias)
Clinical Improvement
High risk Not possible to avoid risk given nature of intervention, and self-report.
Blinding of outcome as-
sessment (detection bias)
Side Effects




Low risk Small percentage of dropout < 10%.
Selective reporting (re-
porting bias)
Unclear risk No protocol described.
Osser 1991  (Continued)
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Methods Study design: randomised trial
Follow-up: 94.1%
Participants Age: 15-50 years old
Country: Thailand (Bangkok)
Setting: single centre Hospital O&G OPD
Diagnosis: mycologic, KOH
Characteristics: non pregnant
Enrolled: 188 (177 evaluable)
Interventions Group 1: fluconazole 150mg (oral), single dose (n = 67)
Group 2: Other - Sertaconozole 500 mg (intra-vaginal), single dose (n = 66)
Group 3: clotrimazole 100 mg, (intra-vaginal), single dose once a day for six consecutive days (n = 55)
Duration: August 31, 2004 to January 30, 2006
Outcomes Accessed at 1 week and 4 weeks
Efficacy
Mycological cure - no yeast growth
Clinical cure - not assessed
Safety: no withdrawals due to adverse events reported
Side effects: quote: "Results showed minimal side effect without adverse event"
Treatment preference: not assessed
Time to first relief: not assessed
Costs: not assessed
Notes Compliance check: not specified
Pharmaceutical industry support: yes - Pacific Healthcare (Thailand) Co., Ltd
This study was included despite the lower age limit being less than the inclusion criteria for this review
(16 years) because only 8/188 participants were in the 15-19 year age range in this trial.
Risk of bias
Bias Authors' judgement Support for judgement
Roongpisuthipong 2010 
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Random sequence genera-
tion (selection bias)
Low risk Computer randomised does not indicate random order, but likely random.
Allocation concealment
(selection bias)





High risk Not possible to avoid risk given nature of intervention.
Blinding of outcome as-
sessment (detection bias)
Time to First Relief
Unclear risk Not reported
Blinding of outcome as-
sessment (detection bias)
Mycological Cure
Low risk Testing done by lab cultures, which are objective outcomes, not influenced by
blinding.
Blinding of outcome as-
sessment (detection bias)
Mycological Improvement
Low risk Testing done by lab cultures, which are objective outcomes, not influenced by
blinding.
Blinding of outcome as-
sessment (detection bias)
Clinical Cure
Unclear risk Outcome not assessed
Blinding of outcome as-
sessment (detection bias)
Clinical Improvement
Unclear risk Outcome not assessed
Blinding of outcome as-
sessment (detection bias)
Side Effects




Low risk 11 total lost to follow-up, evenly distributed. Reasons for lost to follow-up
were not presented. Less than 10% overall.
Selective reporting (re-
porting bias)
Unclear risk No clinical outcome events reported.
Other bias Low risk Groups roughly comparable. Not sure about funding, but possible funding in-





Methods Study design: randomised trial
Follow-up: 7 from the itraconazole group and 5 from the clotrimazole group were excluded because
they were not referred for examination and culture in 10 days after treatment (< 10%).
Participants Age: mean 28.1 ±4.8 (itraconazole group) and 28 ±5.8 (clotrimazole group)
Sanam 2009 
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Country: Iran
Setting: single centre O&G OPD Gynecological outpatient clinic of the University Hospital Amir, Semnan
Diagnosis: mycologic, KOH, visual examination
Characteristics: non-pregnant
Enrolled: 264 (252 evaluable)
Interventions Group 1: itraconazole (oral) 400 mg two divided dose in a day (n = 132)
Group 2: 1% clotrimazole (intra-vaginal) 5 g daily for 6 days (n = 132)
Duration: 1st of June 2006 and 31st of June 2007.
Outcomes Accessed at day 10
Efficacy
Mycological cure: complete eradication
Clinical cure: no clinical signs and symptoms
Safety: no withdrawals due to side effects reported
Side effects: reported (frequency of micturition, dyspareunia)
Treatment preference: not assessed
Time to first relief: not assessed
Costs: not assessed
Notes Compliance: not specified
Pharmaceutical industry support: not specified
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk No description provided.
Allocation concealment
(selection bias)





High risk Not possible to avoid risk given nature of intervention..
Blinding of outcome as-
sessment (detection bias)
Time to First Relief
High risk Not possible to avoid risk given nature of intervention, and self-report.
Blinding of outcome as-
sessment (detection bias)
Mycological Cure
Low risk Testing done by lab cultures, which are objective outcomes, not influenced by
blinding.
Sanam 2009  (Continued)
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Blinding of outcome as-
sessment (detection bias)
Mycological Improvement
Low risk Testing done by lab cultures, which are objective outcomes, not influenced by
blinding.
Blinding of outcome as-
sessment (detection bias)
Clinical Cure
High risk Not possible to avoid risk given nature of intervention, and self-report.
Blinding of outcome as-
sessment (detection bias)
Clinical Improvement
High risk Not possible to avoid risk given nature of intervention, and self-report.
Blinding of outcome as-
sessment (detection bias)
Side Effects




Low risk 12 lost to follow-up (7 and 5) which is < 10% and comparable in both groups.
Selective reporting (re-
porting bias)
Unclear risk No protocol described





Methods Study design: randomised trial
Follow-up: unclear
Participants Age: 18 years and over
Country: USA
Setting: multi-centre; 13 Research facilities (not specified type) across the USA)
Diagnosis: visual examination, KOH, patient report of signs and symptoms, severity score
Characteristics: non-pregnant
Enrolled: 181
Interventions Group 1: butoconazole 5 g vaginal cream (2% site release) single dose (n = 93)
Group 2: fluconazole (oral) 150 mg single dose (n = 88)
Duration: May to November 2003
Outcomes Assessed hourly by patient report
Efficacy
Clinical cure: time to total relief of symptoms (measured in hours)
Mycological cure: not assessed
Safety: no withdrawals due to adverse events reported
Side effects: participant reported a range of adverse events (drug and non drug related)
Treatment preference: not assessed
Seidman 2005 
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Time to first relief: reported - median time to first relief (measured in hours) and proportion of patients
reporting first relief at 12 and 24 hours post-treatment
Costs: not assessed
Notes Compliance checks: yes - administered in investigator's office; 100% compliance. Pharmaceutical in-
dustry support: not specified
Patients were provided with a diary and requested to record the date and time they first started to feel
relief of symptoms and the date and time they had complete relief of symptoms. Outcomes were calcu-
lated using the dosing time and the time reported for each by the patient
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Computer-generated randomisation.
Allocation concealment
(selection bias)





High risk Not possible to avoid risk given nature of intervention.
Blinding of outcome as-
sessment (detection bias)
Time to First Relief
High risk Not possible to avoid risk given nature of intervention, and self-report.
Blinding of outcome as-
sessment (detection bias)
Mycological Cure
Unclear risk Outcome not assessed
Blinding of outcome as-
sessment (detection bias)
Mycological Improvement
Unclear risk Outcome not assessed
Blinding of outcome as-
sessment (detection bias)
Clinical Cure
High risk Not possible to avoid risk given nature of intervention, and self-report.
Blinding of outcome as-
sessment (detection bias)
Clinical Improvement
High risk Not possible to avoid risk given nature of intervention, and self-report.
Blinding of outcome as-
sessment (detection bias)
Side Effects




Unclear risk Not described.
Selective reporting (re-
porting bias)
Unclear risk No culture data.
Other bias Low risk No baseline differences.
Seidman 2005  (Continued)
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Methods Study design: randomised trial
Follow-up: 91.0%
Participants Age: over 15 years of age
Country: Iran
Setting: single centre O&G OPD at the University Shahid Sadoughi hospital in Yazd, Iran
Diagnosis: mycological, clinical symptoms
Characteristics: non-pregnant
Enrolled: 156 (142 evaluable)
Interventions Group1: fluconazole (oral) 150 mg, single dose (n = 72)
Group2: clotrimazole (intra-vaginal) 200 mg for 7 days (n = 70)
Duration: July 2006 and May 2008
Outcomes Accessed at 7 days and 1 month
Efficacy
Mycological cure - mycological absence of yeast
Clinical cure - absence of signs and symptoms
Safety: no withdrawals due to side effects reported
Side effects: reported
Treatment preference: reported (oral)
Time to first relief: not assessed
Costs: not assessed
Notes Compliance: Not specified
Pharmaceutical industry support: Not specified
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk No description provided.
Allocation concealment
(selection bias)





High risk Not possible to avoid risk given nature of intervention.
Sekhavat 2011 
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Blinding of outcome as-
sessment (detection bias)
Time to First Relief
High risk Not possible to avoid risk given nature of intervention, and self-report.
Blinding of outcome as-
sessment (detection bias)
Mycological Cure
Low risk Testing done by lab cultures, which are objective outcomes, not influenced by
blinding.
Blinding of outcome as-
sessment (detection bias)
Mycological Improvement
Low risk Testing done by lab cultures, which are objective outcomes, not influenced by
blinding.
Blinding of outcome as-
sessment (detection bias)
Clinical Cure
High risk Not possible to avoid risk given nature of intervention, and self-report.
Blinding of outcome as-
sessment (detection bias)
Clinical Improvement
High risk Not possible to avoid risk given nature of intervention, and self-report.
Blinding of outcome as-
sessment (detection bias)
Side Effects




Low risk 14 lost to follow-up, unclear which group they were part of, but less than10%.
Selective reporting (re-
porting bias)
Unclear risk No protocol described.





Methods Study design; randomised trial
Follow-up: 95.4%
Participants Age: 18-60 years
Country: USA
Setting: Obstetrics and gynaecology out-patient department
Diagnsosis: microscopic evidence of hyphae from wet mount with gram stain
Characteristics: non-lactating.
Enrolled: 23 (22 evaluable)
Interventions Group 1: fluconazole (oral) 200 mg single dose (n = 12)
Group 2: terconazole 80 mg intra-vaginal suppository daily for 3 days. (n = 10)
Duration: November 1990 through February 1991
Outcomes Assessed at 7-14 days and 28-34 days.
Efficacy
Mycological cure - negative gram stain and wet mount.
Clinical Improvement - favourable clinical response (mycologic cure or improved symptoms.
Slavin 1992 
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Safety: quote: "No adverse drug events were noted"
Side effects: quote: "No adverse drug events were noted"
Treatment preference: reported (oral)
Time to first relief: reported - median and mean time to first relief
Costs: not assessed
Notes Compliance check: yes - participant questioned at 7-14 day follow-up visit). Assessment of "medica-
tion-counts" at the early evaluation was considered 100% compliant.
Pharmaceutical industry support: not specified
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Random number table used.
Allocation concealment
(selection bias)





High risk Not possible to avoid risk given nature of intervention.
Blinding of outcome as-
sessment (detection bias)
Time to First Relief
High risk Not possible to avoid risk given nature of intervention, and self-report.
Blinding of outcome as-
sessment (detection bias)
Mycological Cure
Low risk Testing done by lab cultures, which are objective outcomes, not influenced by
blinding.
Blinding of outcome as-
sessment (detection bias)
Mycological Improvement
Low risk Testing done by lab cultures, which are objective outcomes, not influenced by
blinding.















Low risk No participants lost to follow-up
Selective reporting (re-
porting bias)
Unclear risk No protocol described
Slavin 1992  (Continued)
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Methods Study design: randomised trial
Follow-up: 93.8%
Participants Age: 17- 64 years
Country: USA
Setting: multi-centre (12 centres across the USA); type of setting not specified
Diagnosis: KOH, mycological culture and clinical symptoms.
Characteristics: non-lactating
Enrolled: 429 (358 evaluable)
Interventions Group 1: fluconazole (oral) 150 mg single dose (n = 218)
Group 2: clotrimazole vaginal tablets (one tablet, strength not stated) for 7 days (n = 214)
Duration: not specified
Outcomes Assessed at 14 and 35 days.
Efficacy
Mycological cure - no mycological colonisation
Clinical cure - absence of signs and symptoms of vaginitis.
Safety: no patient discontinued therapy
Side effects: participant reported side effects
Treatment preference: not assessed
Time to first relief: not assessed
Costs: not assessed
Notes Compliance check: done - participant history and pill count. Quote: "No patient discontinued therapy";
100% compliance.
Pharmaceutical industry support: yes
Participants had acute or recurrent vaginal candidiasis. Only the results for acute cases are presented
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk No description provided.
Allocation concealment
(selection bias)





High risk Not possible to avoid risk given nature of intervention.
Sobel 1995 
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Blinding of outcome as-
sessment (detection bias)
Time to First Relief
High risk Not possible to avoid risk given nature of intervention, and self-report.
Blinding of outcome as-
sessment (detection bias)
Mycological Cure
Low risk Testing done by lab cultures, which are objective outcomes, not influenced by
blinding.
Blinding of outcome as-
sessment (detection bias)
Mycological Improvement
Low risk Testing done by lab cultures, which are objective outcomes, not influenced by
blinding.
Blinding of outcome as-
sessment (detection bias)
Clinical Cure
High risk Not possible to avoid risk given nature of intervention, and self-report.
Blinding of outcome as-
sessment (detection bias)
Clinical Improvement
High risk Not possible to avoid risk given nature of intervention, and self-report.
Blinding of outcome as-
sessment (detection bias)
Side Effects




Low risk Less than 10% dropout, roughly equal in both groups
Selective reporting (re-
porting bias)
Unclear risk No protocol described





Methods Study design: randomised trial
Follow-up: 93.0%
Participants Age: 18-65 years
Country: USA
Setting: multi-centre; Primary Care Clinics
Diagnosis: visual examination, KOH and mycological culture
Enrolled: 227 (214 evaluable)
Interventions Group 1: fluconazole (oral) 50 mg for 3 days (n = 111)
Group 2: clotrimazole intra-vaginal tablets 200 mg for 3 days. (n = 116)
Duration: not specified
Outcomes Assessed at 7-10 days and 30-35 days.
Efficacy
Mycological cure - absence of candida species
Clinical cure - complete resolution of signs and symptoms
Stein 1991 
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Safety: reported - quote: "One patient discontinued treatment after she developed diarrhea while re-
ceiving fluconazole"
Side effects: participant reported side effects
Treatment preference: not reported.
Time to first relief: not assessed
Costs: not assessed
Notes Compliance check: not specified
Pharmaceutical industry support: yes - Pfizer Central Research, Groton,CT.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Predetermined code, likely random
Allocation concealment
(selection bias)





High risk Not possible to avoid risk given nature of intervention
Blinding of outcome as-
sessment (detection bias)
Time to First Relief
High risk Not possible to avoid risk given nature of intervention.
Blinding of outcome as-
sessment (detection bias)
Mycological Cure
Low risk Testing done by lab cultures, which are objective outcomes, not influenced by
blinding.
Blinding of outcome as-
sessment (detection bias)
Mycological Improvement
Low risk Testing done by lab cultures, which are objective outcomes, not influenced by
blinding.
Blinding of outcome as-
sessment (detection bias)
Clinical Cure
High risk Not possible to avoid risk given nature of intervention, and self-report.
Blinding of outcome as-
sessment (detection bias)
Clinical Improvement
High risk Not possible to avoid risk given nature of intervention, and self-report.
Blinding of outcome as-
sessment (detection bias)
Side Effects




Low risk Five of 95 lost to follow-up
Selective reporting (re-
porting bias)
Unclear risk No protocol described.
Other bias Low risk Groups comparable at baseline.
Stein 1991  (Continued)
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Methods Study design: randomised trial (three arm)
Follow-up: 94.7% follow-up at first evaluation time point and 63.2% follow-up at second evaluation
time point
Participants Age: 18 years and over
Country: USA
Setting: not specified
Diagnosis: KOH and clinical symptoms and mycological culture.
Enrolled: 95 (90 evaluable)
Interventions Group 1: itraconazole (oral) 200 mg for 3 days (n = 50
Group 2: clotrimazole vaginal tablets 200 mg for 3 days (n = 23)
Group 3: placebo: n = 22
Duration: not specified
Outcomes Assessed at 1 and 4 weeks.
Efficacy
Mycological cure - absence of Candida species
Clinical cure - complete resolution of signs and symptoms
Safety: quote: "No patients enrolled in this study discontinued treatment because of an adverse event"
Side effects: reported
Treatment preference: reported.
Time to first relief: not assessed
Costs: not assessed
Notes Compliance check: not reported
Pharmaceutical industry support: yes - Research Foundation, Piscataway, N.J.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk No description provided.
Allocation concealment
(selection bias)





High risk Not possible to avoid risk given nature of intervention.
Blinding of outcome as-
sessment (detection bias)
Time to First Relief
High risk Not possible to avoid risk given nature of intervention, and self-report.
Stein 1993 
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Blinding of outcome as-
sessment (detection bias)
Mycological Cure
Low risk Testing done by lab cultures, which are objective outcomes, not influenced by
blinding.
Blinding of outcome as-
sessment (detection bias)
Mycological Improvement
Low risk Testing done by lab cultures, which are objective outcomes, not influenced by
blinding.
Blinding of outcome as-
sessment (detection bias)
Clinical Cure
High risk Not possible to avoid risk given nature of intervention, and self-report.
Blinding of outcome as-
sessment (detection bias)
Clinical Improvement
High risk Not possible to avoid risk given nature of intervention, and self-report.
Blinding of outcome as-
sessment (detection bias)
Side Effects




High risk Overall, 60/95 or 63.2% of participants were assessed at four week follow-up.
Selective reporting (re-
porting bias)
Unclear risk No protocol described.





Methods Study design: randomised trial (multi-centre)
Follow-up: not calculable
Participants Age: 18 years and over
Country: Finland
Setting: non-specified multi-centre setting - possibly gynaecologist/physician office/practice
Diagnosis: mycological culture and clinical symptoms
Enrolled: 125 (63 fluconazole and 62 miconazole) 20 patients were negative for yeast culture after ran-
domisation and removed) 105 evaluable
Interventions Group 1: fluconazole (oral) 150 mg single dose (n = 56)
Group 2: miconazole 400 mg pessary for 3 days (n = 49)
Duration: not specified
Outcomes Assessed at 1 week and 1 month
Efficacy
Mycologicalcure - negative yeast culture
Clinical cure - asymptomatic
Safety: quote: "One patient discontinued the treatment because of a severe burning sensation in the
vagina" - miconazole group
Timonen 1992a 
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Side effects: reported
Treatment preference: reported
Time to first relief: not assessed
Costs: not assessed
Notes Compliance check: not reported
Pharmaceutical industry support: not reported
Results calculated from percentages quoted by authors. Five itraconazole and eight econazole partic-
ipants had chronic vaginal candidiasis (i.e. 3 or more episodes in previous 12 months) - results not re-
ported separately
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk No description provided.
Allocation concealment
(selection bias)





High risk Not possible to avoid risk given nature of intervention.
Blinding of outcome as-
sessment (detection bias)
Time to First Relief
High risk Not possible to avoid risk given nature of intervention, and self-report.
Blinding of outcome as-
sessment (detection bias)
Mycological Cure
Low risk Testing done by lab cultures, which are objective outcomes, not influenced by
blinding.
Blinding of outcome as-
sessment (detection bias)
Mycological Improvement
Low risk Testing done by lab cultures, which are objective outcomes, not influenced by
blinding.
Blinding of outcome as-
sessment (detection bias)
Clinical Cure
High risk Not possible to avoid risk given nature of intervention, and self-report.
Blinding of outcome as-
sessment (detection bias)
Clinical Improvement
High risk Not possible to avoid risk given nature of intervention, and self-report.
Blinding of outcome as-
sessment (detection bias)
Side Effects




Unclear risk Not calculable.
Timonen 1992a  (Continued)
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Selective reporting (re-
porting bias)
Unclear risk No protocol described.





Methods Study design: randomised trial
Follow-up: not calculable
Participants Age: 20 to 58 years
Country: Finland
Setting: multi-centre; three outpatient sites (not specified)
Diagnosis: mycological culture
Enrolled: 81
Interventions Group 1: itraconazole 200 mg for 3 days. (n = 40)
Group 2: econazole 150 mg for 3 days. (n = 41)
Duration: Two years (not specified)
Outcomes Assessed at 1 and 2 weeks
Efficacy
Mycological cure - negative gram stain and wet mount.
Clinical Improvement - favourable clinical response (mycologic cure or improved symptoms.
Safety: quote: "None of the patients discontinued treatment because of an adverse event"
Side effects: reported
Treatment preference: reported
Time to first relief: reported - proportion of patients reporting alleviation of symptoms each day post-
treatment
Costs: not assessed
Notes Compliance check: not reported
Pharmaceutical industry support: yes - Orion Pharmaceutica, Espoo, Finland
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk No description provided.
Allocation concealment
(selection bias)





Low risk Double-blind trial (double-dummy).
Timonen 1992b 
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Blinding of outcome as-
sessment (detection bias)
Time to First Relief
High risk Not possible to avoid risk given nature of intervention, and self-report.
Blinding of outcome as-
sessment (detection bias)
Mycological Cure
Low risk Testing done by lab cultures, which are objective outcomes, not influenced by
blinding.
Blinding of outcome as-
sessment (detection bias)
Mycological Improvement
Low risk Testing done by lab cultures, which are objective outcomes, not influenced by
blinding.















Unclear risk Not calculable.
Selective reporting (re-
porting bias)
Unclear risk No protocol described





Methods Study design: randomised trial (multi-centre)
Follow-up: 68.7%
Participants Age: 18 years and over
Country: UK
Setting: Genito-urinary medicine clinics in 17 hospitals across UK
Diagnosis: visual examination, mycological culture and clinical symptoms (vulvitis, vaginitis).
Enrolled: 262 (214 evaluable)
Interventions Group 1: itraconazole 200 mg two times a day for one day (n = 109)
Group 2: clotrimazole 500 mg - Single dose (n = 105)
Duration: not specified
Outcomes Assessed at 5-10 days and 30-40 days:
Efficacy
Clinical cure: not assessed
Tobin 1992 
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Mycological cure: negative culture for Candida species.
Safety: no withdrawals due to adverse events
Side effects: not reported
Treatment preference: reported
Time to first relief: reported - mean time to first relief
Costs: not reported
Notes Compliance Check: not reported
Pharmaceutical industry support: yes - Janssen Pharmaceutical Limited, Oxford, UK
Participants permitted to use quote: "bland soothing agent" and to record use in diary.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk No description provided
Allocation concealment
(selection bias)





High risk Not possible to avoid risk given nature of intervention.
Blinding of outcome as-
sessment (detection bias)
Time to First Relief
High risk Not possible to avoid risk given nature of intervention, and self-report.
Blinding of outcome as-
sessment (detection bias)
Mycological Cure
Low risk Testing done by lab cultures, which are objective outcomes, not influenced by
blinding.
Blinding of outcome as-
sessment (detection bias)
Mycological Improvement
Low risk Testing done by lab cultures, which are objective outcomes, not influenced by
blinding.
Blinding of outcome as-
sessment (detection bias)
Clinical Cure
High risk Not possible to avoid risk given nature of intervention, and self-report.
Blinding of outcome as-
sessment (detection bias)
Clinical Improvement
High risk Not possible to avoid risk given nature of intervention, and self-report.
Blinding of outcome as-
sessment (detection bias)
Side Effects




High risk Twenty per cent lost to follow-up.
Tobin 1992  (Continued)
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Selective reporting (re-
porting bias)
Unclear risk No protocol described





Methods Study design: randomised trial (multi-centre)
Follow-up: 93.9%
Participants Age: 18-60 years
Country: the Netherlands
Setting: Out-patients - multi-centre department or centres not specified
Diagnosis: mycological culture and clinical symptoms
Characteristics: non-lactating
Enrolled: 99 (93 evaluable)
Interventions Group 1: fluconazole (oral) 150 mg single dose (n = 49)
Group 2: Miconazole 1200mg intra-vaginal single dose (n = 50)
Duration: Not specified
Outcomes Assessed at 6-10 days (short-term) and 22-60 days (long-term) follow-up.
Efficacy
Mycological cure - complete absence of Candida species at follow-up.
Clinical cure - physician subjective global assessment.
Safety: no withdrawals due to side effects reported
Side effects: participant reported side effects.
Treatment preference: reported
Time to first relief: not assessed
Costs: not reported
Notes Compliance check: not reported
Pharmaceutical industry support: not specified
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk No description provided.
Allocation concealment
(selection bias)





Low risk Double-blind trial (double-dummy).
Van Heusden 1990 
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Blinding of outcome as-
sessment (detection bias)
Time to First Relief
High risk Not possible to avoid risk given nature of intervention, and self-report.
Blinding of outcome as-
sessment (detection bias)
Mycological Cure
Low risk Testing done by lab cultures, which are objective outcomes, not influenced by
blinding.
Blinding of outcome as-
sessment (detection bias)
Mycological Improvement
Low risk Testing done by lab cultures, which are objective outcomes, not influenced by
blinding.















Low risk Small number but all in one group,< 10%
Selective reporting (re-
porting bias)
Unclear risk No protocol described.





Methods Study design: randomised trial (multi-centre)
Follow-up: not-calculable
Participants Age: 18-65 years
Country: the Netherlands
Setting: Obstetrics and Gynaecology Out-Patient Department and General Practices
Diagnosis: mycological culture and clinical symptoms
Characteristics: non-lactating
Enrolled: 741 (693 evaluable)
Interventions Group 1: fluconazole (oral) 150 mg single dose (n = not clearly reported)
Group 2: clotrimazole intra-vaginal tablets 500 mg single dose (n = not clearly reported)
Duration: Not specified
Outcomes Assessed at 7 and 28 days
Efficacy
Mycological cure: complete absence of Candida species
Van Heusden 1994 
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Clinical cure: signs and symptoms scored by patient and overall efficacy rated by both physician and
patient
Safety: No withdrawals due to side effects reported
Side effects: reported.
Treatment preference: reported
Time to first relief: not reported
Costs: not reported
Notes Compliance check: not reported
Pharmaceutical industry support: not specified
Results calculated from percentages quoted by authors
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Compute- generated list, likely random.
Allocation concealment
(selection bias)





High risk Not possible to avoid risk given nature of intervention.
Blinding of outcome as-
sessment (detection bias)
Time to First Relief
High risk Not possible to avoid risk given nature of intervention, and self-report.
Blinding of outcome as-
sessment (detection bias)
Mycological Cure
Low risk Testing done by lab cultures, which are objective outcomes, not influenced by
blinding.
Blinding of outcome as-
sessment (detection bias)
Mycological Improvement
Low risk Testing done by lab cultures, which are objective outcomes, not influenced by
blinding.
Blinding of outcome as-
sessment (detection bias)
Clinical Cure
High risk Not possible to avoid risk given nature of intervention, and self-report.
Blinding of outcome as-
sessment (detection bias)
Clinical Improvement
High risk Not possible to avoid risk given nature of intervention, and self-report.
Blinding of outcome as-
sessment (detection bias)
Side Effects




Low risk Only 6.4% lost to follow-up.
Van Heusden 1994  (Continued)
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Selective reporting (re-
porting bias)
Unclear risk No protocol described.





Methods Study design: randomised trial
Follow-up: 100%
Participants Age: 16-53 years
Country: UK
Setting: Genito-urinary Medicine Clinic
Diagnosis: mycological and/or microscopic.
Enrolled: 229
Interventions Group 1: clotrimazole pessary 500 mg (single dose) and 1% cream. (n = 82)
Group 2: fluconazole (oral) 150 mg single dose (n = 72)
Group 3: itraconazole (oral) 200 mg (single dose) (n = 75)
Duration: Not specified
Outcomes Assessed at 7-10 days.
Efficacy
Mycological cure - negative culture and tests for Candida
Clinical cure - assessed by physician
Safety: not reported
Side effects: not reported
Treatment preference: not reported
Time to first relief: not reported
Costs: not reported
Notes Compliance check: not reported
Pharmaceutical industry support: not specified
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk No description provided.
Allocation concealment
(selection bias)




High risk not possible given nature of intervention
Woolley 1995 
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All outcomes
Blinding of outcome as-
sessment (detection bias)
Time to First Relief
High risk Not possible to avoid risk given nature of intervention, and self-report.
Blinding of outcome as-
sessment (detection bias)
Mycological Cure
Low risk Testing done by lab cultures, which are objective outcomes, not influenced by
blinding.
Blinding of outcome as-
sessment (detection bias)
Mycological Improvement
Low risk Testing done by lab cultures, which are objective outcomes, not influenced by
blinding.
Blinding of outcome as-
sessment (detection bias)
Clinical Cure
High risk Not possible to avoid risk given nature of intervention, and self-report.
Blinding of outcome as-
sessment (detection bias)
Clinical Improvement
High risk Not possible to avoid risk given nature of intervention, and self-report.
Blinding of outcome as-
sessment (detection bias)
Side Effects




Low risk No participants lost to follow-up.
Selective reporting (re-
porting bias)
Unclear risk No protocol described.





Methods Study design: randomised trial
Follow-up:uUnclear, insufficient data presented.
Participants Age: 18 - 45 years
Country; Croatia
Settings: General Practice (not specified)
Diagnosis: visual examination, clinical symptoms, confirmed microscopically
Characteristics: not specified
Enrolled: 246 episodes (of thrush) 83 participants
Interventions Group 1: fluconazole (oral) 150 mg single dose (n = 71 episodes)
Group 2: clotrimazole (intra-vaginal) 200 mg daily for 3 days (n = 55 episodes)
Škerk V 2006 
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Duration: June 1, 2006 until July 31, 2006,
Outcomes Assessed up to 2 months following treatment allocation.
Efficacy
Clinical cure: successful treatment, recurrent VVC as reported by patients
Mycological cure: not reported
Safety: no withdrawals due to side effects reported
Side effects: reported: quote: "There were no side effects of the doctor trial" (per our translation)
Treatment preference: not assessed
Time to first relief: not assessed
Costs: not assessed
Notes Compliance check: not specified
Pharmaceutical industry support: not specified
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk No description provided.
Allocation concealment
(selection bias)





High risk Not possible to avoid risk given nature of intervention.
Blinding of outcome as-
sessment (detection bias)
Time to First Relief
Unclear risk Outcome not assessed.
Blinding of outcome as-
sessment (detection bias)
Mycological Cure
Unclear risk Outcome not assessed.
Blinding of outcome as-
sessment (detection bias)
Mycological Improvement
Unclear risk Outcome not assessed.
Blinding of outcome as-
sessment (detection bias)
Clinical Cure
Unclear risk Not possible to avoid risk given nature of intervention, and self-report.
Blinding of outcome as-
sessment (detection bias)
Clinical Improvement
Unclear risk Not possible to avoid risk given nature of intervention, and self-report.
Blinding of outcome as-
sessment (detection bias)
Side Effects
Unclear risk Not possible to avoid risk given nature of intervention, and self-report.
Škerk V 2006  (Continued)
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Unclear risk Numbers in group not specified.
Selective reporting (re-
porting bias)
Unclear risk No protocol described.
Other bias Unclear risk No data provided for baseline values. See table 1 for baseline imbalance.
Škerk V 2006  (Continued)
ITT: intention-to-treat
O&G OPD = Obstetrics and Gynaecology Out-Patient Department
KOH = potassium hydroxide
VVC: vulvovaginal candidiasis
 
Characteristics of excluded studies [ordered by study ID]
 
Study Reason for exclusion
EUCTR2005-001360-31-IT Contacted Abiogen Pharma July 12, 2018 and October 8, 2018 using online contact form to enquire
about the open treatment arm to determine eligibility. Study has been completed. Acknowledg-
ment of contact received only; no response to query received. Website: https://www.abiogen.it/en/
Fan 2015 Did not meet inclusion criteria (involved women with complicated vulvovaginal candidiasis)
Fong 1992 Did not meet inclusion criteria (involved women with complicated vulvovaginal candidiasis)
Herzog 1989 Random allocation not specified.
Li 2015 Did not meet inclusion criteria (involved women with complicated vulvovaginal candidiasis).
Lopez Olmos 1994 Random allocation not specified.
Mikamo 1998 The review authors believe that the some of the participants reported in this trial were reported in
a previous included trial Mikamo 1995). This trial has been excluded to avoid duplicate use of data.
Wermeling 1992 Abstract only - insufficient information provided.
Zhou 2016 Did not meet inclusion criteria (involved women with complicated vulvovaginal candidiasis).
 
 
D A T A   A N D   A N A L Y S E S
 
Comparison 1.   Oral versus Intra-vaginal





Statistical method Effect size
1.1 Clinical cure (short term) 13 1859 Odds Ratio (M-H, Fixed, 95% CI) 1.14 [0.91, 1.43]
1.1.1 Fluconazole vs Clotrimazole 6 809 Odds Ratio (M-H, Fixed, 95% CI) 1.13 [0.81, 1.58]
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Statistical method Effect size
1.1.2 Itraconazole vs Clotrimazole 3 436 Odds Ratio (M-H, Fixed, 95% CI) 1.41 [0.86, 2.33]
1.1.3 Fluconazole vs Miconazole 1 93 Odds Ratio (M-H, Fixed, 95% CI) 1.23 [0.45, 3.42]
1.1.4 Fluconazole vs Econazole 1 230 Odds Ratio (M-H, Fixed, 95% CI) 1.51 [0.46, 4.89]
1.1.5 Itraconazole vs Econazole 1 75 Odds Ratio (M-H, Fixed, 95% CI) 1.70 [0.64, 4.55]
1.1.6 Fluconazole vs Butocona-
zole
1 136 Odds Ratio (M-H, Fixed, 95% CI) 0.66 [0.33, 1.30]
1.1.7 Fluconazole vs Fenticona-
zole
1 80 Odds Ratio (M-H, Fixed, 95% CI) 0.89 [0.34, 2.33]
1.2 Clinical cure (long term) 9 1042 Odds Ratio (M-H, Fixed, 95% CI) 1.07 [0.77, 1.50]
1.2.1 Fluconazole vs Clotrimzole 4 564 Odds Ratio (M-H, Fixed, 95% CI) 1.01 [0.65, 1.57]
1.2.2 Itraconazole vs Clotrimazole 1 53 Odds Ratio (M-H, Fixed, 95% CI) 2.15 [0.63, 7.37]
1.2.3 Fluconazole vs Miconazole 1 93 Odds Ratio (M-H, Fixed, 95% CI) 1.54 [0.51, 4.66]
1.2.4 Fluconazole vs Econazole 1 177 Odds Ratio (M-H, Fixed, 95% CI) 1.05 [0.40, 2.72]
1.2.5 Itraconazole vs Econazole 1 75 Odds Ratio (M-H, Fixed, 95% CI) 0.69 [0.20, 2.41]
1.2.6 Fluconazole vs Fenticona-
zole
1 80 Odds Ratio (M-H, Fixed, 95% CI) 0.65 [0.10, 4.11]
1.3 Mycological cure (short term) 19 3057 Odds Ratio (M-H, Fixed, 95% CI) 1.24 [1.03, 1.50]
1.3.1 Fluconazole vs Clotrimazole 12 1927 Odds Ratio (M-H, Fixed, 95% CI) 1.18 [0.93, 1.49]
1.3.2 Itraconazole vs Clotrimazole 4 631 Odds Ratio (M-H, Fixed, 95% CI) 1.12 [0.73, 1.71]
1.3.3 Fluconazole vs Miconazole 2 194 Odds Ratio (M-H, Fixed, 95% CI) 0.74 [0.26, 2.06]
1.3.4 Fluconazole vs Econazole 1 230 Odds Ratio (M-H, Fixed, 95% CI) 1.93 [0.97, 3.83]
1.3.5 Itraconazole vs Econazole 1 75 Odds Ratio (M-H, Fixed, 95% CI) 3.55 [1.29, 9.77]
1.4 Mycological cure (long term) 13 1661 Odds Ratio (M-H, Fixed, 95% CI) 1.29 [1.05, 1.60]
1.4.1 Fluconazole vs Clotrimazole 7 1015 Odds Ratio (M-H, Fixed, 95% CI) 1.31 [1.00, 1.71]
1.4.2 Itraconazole vs Clotrimazole 2 200 Odds Ratio (M-H, Fixed, 95% CI) 1.09 [0.60, 1.98]
1.4.3 Fluconazole vs Miconazole 2 194 Odds Ratio (M-H, Fixed, 95% CI) 0.72 [0.37, 1.40]
1.4.4 Fluconazole vs Econazole 1 177 Odds Ratio (M-H, Fixed, 95% CI) 2.17 [1.06, 4.42]
1.4.5 Itraconazole vs Econazole 1 75 Odds Ratio (M-H, Fixed, 95% CI) 2.26 [0.89, 5.74]
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Statistical method Effect size
1.5 Safety - number of with-
drawals due to adverse events
23   Other data No numeric data
1.6 Side effects 16 3155 Odds Ratio (M-H, Fixed, 95% CI) 1.04 [0.84, 1.29]
1.6.1 Fluconazole vs Clotrimazole 7 1753 Odds Ratio (M-H, Fixed, 95% CI) 1.30 [0.97, 1.74]
1.6.2 Itraconazole vs Clotrimazole 2 320 Odds Ratio (M-H, Fixed, 95% CI) 1.13 [0.54, 2.37]
1.6.3 Fluconazole vs Fenticona-
zole
1 80 Odds Ratio (M-H, Fixed, 95% CI) 1.54 [0.24, 9.75]
1.6.4 Fluconazole vs Miconazole 3 505 Odds Ratio (M-H, Fixed, 95% CI) 0.75 [0.43, 1.31]
1.6.5 Fluconazole vs Econazole 1 235 Odds Ratio (M-H, Fixed, 95% CI) 0.35 [0.17, 0.74]
1.6.6 Fluconazole vs Butocona-
zole
1 181 Odds Ratio (M-H, Fixed, 95% CI) 1.92 [0.85, 4.33]
1.6.7 Itraconazole vs Econazole 1 81 Odds Ratio (M-H, Fixed, 95% CI) 0.46 [0.13, 1.66]
1.7 Treatment preference 12   Other data No numeric data
1.8 Time to first relief 10   Other data No numeric data
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Analysis 1.1.   Comparison 1: Oral versus Intra-vaginal, Outcome 1: Clinical cure (short term)
Study or Subgroup









Heterogeneity: Chi² = 9.66, df = 5 (P = 0.09); I² = 48%
Test for overall effect: Z = 0.74 (P = 0.46)






Heterogeneity: Chi² = 0.88, df = 2 (P = 0.64); I² = 0%
Test for overall effect: Z = 1.36 (P = 0.17)





Test for overall effect: Z = 0.40 (P = 0.69)





Test for overall effect: Z = 0.68 (P = 0.50)





Test for overall effect: Z = 1.07 (P = 0.29)





Test for overall effect: Z = 1.21 (P = 0.23)














































































































M-H, Fixed, 95% CI
1.61 [0.49 , 5.28]
3.77 [0.15 , 95.82]
1.97 [0.97 , 4.00]
1.33 [0.77 , 2.30]
0.71 [0.30 , 1.66]
0.40 [0.16 , 1.00]
1.13 [0.81 , 1.58]
1.71 [0.85 , 3.44]
1.45 [0.47 , 4.43]
0.97 [0.37 , 2.53]
1.41 [0.86 , 2.33]
1.23 [0.45 , 3.42]
1.23 [0.45 , 3.42]
1.51 [0.46 , 4.89]
1.51 [0.46 , 4.89]
1.70 [0.64 , 4.55]
1.70 [0.64 , 4.55]
0.66 [0.33 , 1.30]
0.66 [0.33 , 1.30]
0.89 [0.34 , 2.33]
Odds Ratio
M-H, Fixed, 95% CI
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Analysis 1.1.   (Continued)





Test for overall effect: Z = 0.25 (P = 0.80)
Total (95% CI)
Total events:
Heterogeneity: Chi² = 14.90, df = 13 (P = 0.31); I² = 13%
Test for overall effect: Z = 1.14 (P = 0.26)
















0.89 [0.34 , 2.33]
0.89 [0.34 , 2.33]
1.14 [0.91 , 1.43]
0.1 0.2 0.5 1 2 5 10
Favours intra-vaginal Favours oral
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Analysis 1.2.   Comparison 1: Oral versus Intra-vaginal, Outcome 2: Clinical cure (long term)
Study or Subgroup







Heterogeneity: Chi² = 2.60, df = 3 (P = 0.46); I² = 0%
Test for overall effect: Z = 0.06 (P = 0.95)





Test for overall effect: Z = 1.22 (P = 0.22)





Test for overall effect: Z = 0.77 (P = 0.44)





Test for overall effect: Z = 0.10 (P = 0.92)





Test for overall effect: Z = 0.58 (P = 0.56)





Test for overall effect: Z = 0.46 (P = 0.65)
Total (95% CI)
Total events:
Heterogeneity: Chi² = 5.08, df = 8 (P = 0.75); I² = 0%
Test for overall effect: Z = 0.40 (P = 0.69)

























































































M-H, Fixed, 95% CI
5.44 [0.21 , 144.10]
0.91 [0.48 , 1.71]
0.80 [0.37 , 1.71]
1.84 [0.60 , 5.67]
1.01 [0.65 , 1.57]
2.15 [0.63 , 7.37]
2.15 [0.63 , 7.37]
1.54 [0.51 , 4.66]
1.54 [0.51 , 4.66]
1.05 [0.40 , 2.72]
1.05 [0.40 , 2.72]
0.69 [0.20 , 2.41]
0.69 [0.20 , 2.41]
0.65 [0.10 , 4.11]
0.65 [0.10 , 4.11]
1.07 [0.77 , 1.50]
Odds Ratio
M-H, Fixed, 95% CI
0.1 0.2 0.5 1 2 5 10
Favours intra-vaginal Favours oral
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Analysis 1.3.   Comparison 1: Oral versus Intra-vaginal, Outcome 3: Mycological cure (short term)
Study or Subgroup















Heterogeneity: Chi² = 12.78, df = 11 (P = 0.31); I² = 14%
Test for overall effect: Z = 1.36 (P = 0.17)







Heterogeneity: Chi² = 5.11, df = 3 (P = 0.16); I² = 41%
Test for overall effect: Z = 0.52 (P = 0.61)





Heterogeneity: Chi² = 0.61, df = 1 (P = 0.43); I² = 0%
Test for overall effect: Z = 0.59 (P = 0.56)





Test for overall effect: Z = 1.88 (P = 0.06)


















































































































































M-H, Fixed, 95% CI
2.22 [0.46 , 10.79]
1.26 [0.71 , 2.24]
5.00 [0.42 , 59.66]
1.61 [0.49 , 5.28]
0.25 [0.01 , 5.98]
0.94 [0.60 , 1.48]
1.77 [0.80 , 3.95]
0.95 [0.37 , 2.49]
2.14 [0.96 , 4.79]
1.36 [0.76 , 2.44]
0.64 [0.23 , 1.75]
0.26 [0.05 , 1.21]
1.18 [0.93 , 1.49]
1.71 [0.85 , 3.44]
0.14 [0.02 , 1.17]
1.10 [0.58 , 2.07]
1.23 [0.20 , 7.68]
1.12 [0.73 , 1.71]
0.60 [0.18 , 1.92]
1.75 [0.15 , 20.00]
0.74 [0.26 , 2.06]
1.93 [0.97 , 3.83]
1.93 [0.97 , 3.83]
3.55 [1.29 , 9.77]
3.55 [1.29 , 9.77]
1.24 [1.03 , 1.50]
Odds Ratio
M-H, Fixed, 95% CI
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Analysis 1.3.   (Continued)
Total (95% CI)
Total events:
Heterogeneity: Chi² = 25.22, df = 19 (P = 0.15); I² = 25%
Test for overall effect: Z = 2.24 (P = 0.02)




1533 100.0% 1.24 [1.03 , 1.50]
0.1 0.2 0.5 1 2 5 10
Favours intra-vaginal Favours oral
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Analysis 1.4.   Comparison 1: Oral versus Intra-vaginal, Outcome 4: Mycological cure (long term)
Study or Subgroup










Heterogeneity: Chi² = 11.06, df = 6 (P = 0.09); I² = 46%
Test for overall effect: Z = 1.96 (P = 0.05)





Heterogeneity: Chi² = 0.21, df = 1 (P = 0.64); I² = 0%
Test for overall effect: Z = 0.27 (P = 0.79)





Heterogeneity: Chi² = 0.10, df = 1 (P = 0.75); I² = 0%
Test for overall effect: Z = 0.96 (P = 0.34)





Test for overall effect: Z = 2.12 (P = 0.03)





Test for overall effect: Z = 1.72 (P = 0.09)
Total (95% CI)
Total events:
Heterogeneity: Chi² = 18.04, df = 12 (P = 0.11); I² = 33%
Test for overall effect: Z = 2.38 (P = 0.02)








































































































M-H, Fixed, 95% CI
4.44 [0.98 , 20.07]
1.56 [0.97 , 2.53]
5.44 [0.21 , 144.10]
2.00 [0.97 , 4.13]
0.78 [0.35 , 1.75]
1.23 [0.73 , 2.08]
0.52 [0.22 , 1.24]
1.31 [1.00 , 1.71]
1.55 [0.31 , 7.82]
1.03 [0.54 , 1.96]
1.09 [0.60 , 1.98]
0.79 [0.32 , 1.95]
0.64 [0.24 , 1.73]
0.72 [0.37 , 1.40]
2.17 [1.06 , 4.42]
2.17 [1.06 , 4.42]
2.26 [0.89 , 5.74]
2.26 [0.89 , 5.74]
1.29 [1.05 , 1.60]
Odds Ratio
M-H, Fixed, 95% CI
0.1 0.2 0.5 1 2 5 10
Favours intra-vaginal Favours oral
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Analysis 1.5.   Comparison 1: Oral versus Intra-vaginal, Outcome
5: Safety - number of withdrawals due to adverse events
 
Safety - number of withdrawals due to adverse events
Study Any participants withdrew due to adverse effects Comments
ACCELERATE 2002 Yes "One subject experienced severe vulvovaginal itch-
ing, burning, and irritation and was withdrawn from
the study" - MONISTAT-1 Combination Pack treatment
group
Adetoro 1990 No "Both treatments were well-tolerated. One patient re-
ceiving fluconazole and two patients receiving clotri-
mazole reported mild, self-limiting side effects". There
were no withdrawals in this study.
Andersen 1989 No "Both treatments proved to be well tolerated and
safe"
Goode 1992 No "Reported side effects were minimal in both treat-
ment groups"
Mendling 2004 No "Serious or unexpected events were not observed in
any of the treatment groups."
Mikamo 1995 No "Neither adverse side effects to the drug nor abnormal
laboratory values were noted during the treatment or
observation periods"
Murina 2012 No Translation from Italian - no patient belonging to the
two groups had to suspend treatment due to the pres-
ence of severe side effects
O-Prasertsawat 1995 No "All side effects were minimal".
Osser 1991 No No withdrawals due to side effects were reported
Roongpisuthipong 2010 No "Results showed minimal side-effect without adverse
event"
Sanam 2009 No No withdrawals due to side effects were reported
Seidman 2005 No No withdrawals due to adverse events were reported
Sekhavat 2011 No No withdrawals due to side effects were reported
Slavin 1992 No "No adverse drug effects were noted"
Sobel 1995 No "No patient discontinued therapy"
Stein 1991 Yes "One patient discontinued treatment after she devel-
oped diarrhea while receiving fluconazole"
Stein 1993 No "No patients enrolled in this study discontinued treat-
ment because of an adverse event"
Timonen 1992a Yes "One patient discontinued the treatment because of a
severe burning sensation in the vagina" - miconazole
group
Timonen 1992b No "None of the patients discontinued treatment be-
cause of an adverse event"
Tobin 1992 No The reasons for withdrawals were reported and ad-
verse effects was not one reported as a reason
Van Heusden 1990 No "The incidence of side effects was low."No with-
drawals due to side effects were reported
Van Heusden 1994 No No withdrawals due to side effects were reported
Škerk V 2006 No "There were no side effects of treatment"
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Analysis 1.6.   Comparison 1: Oral versus Intra-vaginal, Outcome 6: Side e;ects
Study or Subgroup










Heterogeneity: Chi² = 11.47, df = 6 (P = 0.07); I² = 48%
Test for overall effect: Z = 1.75 (P = 0.08)





Heterogeneity: Chi² = 7.70, df = 1 (P = 0.006); I² = 87%
Test for overall effect: Z = 0.33 (P = 0.74)





Test for overall effect: Z = 0.46 (P = 0.65)






Heterogeneity: Chi² = 2.34, df = 2 (P = 0.31); I² = 14%
Test for overall effect: Z = 1.01 (P = 0.31)





Test for overall effect: Z = 2.76 (P = 0.006)





Test for overall effect: Z = 1.56 (P = 0.12)




























































































































M-H, Fixed, 95% CI
0.41 [0.03 , 4.88]
0.85 [0.32 , 2.25]
1.13 [0.64 , 1.98]
0.29 [0.09 , 0.98]
1.67 [0.38 , 7.26]
1.77 [1.11 , 2.81]
2.85 [0.97 , 8.40]
1.30 [0.97 , 1.74]
0.44 [0.16 , 1.20]
10.42 [1.28 , 84.75]
1.13 [0.54 , 2.37]
1.54 [0.24 , 9.75]
1.54 [0.24 , 9.75]
1.05 [0.52 , 2.15]
0.43 [0.13 , 1.39]
0.38 [0.07 , 2.08]
0.75 [0.43 , 1.31]
0.35 [0.17 , 0.74]
0.35 [0.17 , 0.74]
1.92 [0.85 , 4.33]
1.92 [0.85 , 4.33]
0.46 [0.13 , 1.66]
0.46 [0.13 , 1.66]
Odds Ratio
M-H, Fixed, 95% CI
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Test for overall effect: Z = 1.19 (P = 0.24)
Total (95% CI)
Total events:
Heterogeneity: Chi² = 36.82, df = 15 (P = 0.001); I² = 59%
Test for overall effect: Z = 0.38 (P = 0.71)
















0.46 [0.13 , 1.66]
0.46 [0.13 , 1.66]
1.04 [0.84 , 1.29]
0.05 0.2 1 5 20
Favours oral Favours intra-vaginal
 
 







Notes n SoO vote count
Adetoro 1990     No numbers provided.
Comment in paper: "It
was also noted that vir-
tually all treated patients
preferred oral treatment
to the more convention-
al intravaginal therapy."
43 Oral
Andersen 1989 25 (65.8) 0 (0) Data were from only one
treatment group (flu-
conazole treated group)
at only one centre.
45 Oral
Coric 2006 93 (78.2) 26 (21.8)   119 Oral








17.9% of the women ad-
ministered fluconazole
expressed no opinion.




Sekhavat 2011     Comment in paper:
"More than 97% patients




clotrimazole 68.6% (p =
0.001)."
142 Oral
Slavin 1992     Comment in paper:
"Seventy-three percent
of the study patients pre-
ferred oral therapy
compared to intravagi-
nal for the treatment of
candida vaginitis."
22 Oral
Stein 1993     No numbers provided.
Comment in paper: "Itra-
conazole therapy was
highly favored over ther-
apy with clotrimazole in
our survey of patients".
95 Oral





Fluconazole group 1 (1.9)
Miconazole group 3 (6.4)
(4.9)
No preference:
Fluconazole group 3 (5.6)
Miconazole group 11
(23.4)
I think the numbers are
65 and 6, but not given in
paper.
15% did not state a pref-
erence
101 Oral
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Timonen 1992b (80.2) (4.9) 15% did not state a pref-
erence
81 Oral







but it is not recorded
whether the previous
treatments were oral or
vaginal.
180 N/A
Van Heusden 1990 43 (46.2) 4 (4.3) 46 (49.5%) had no prefer-
ence
93 No preference
Van Heusden 1994 (52) (17) In addition, 26% had no





Analysis 1.8.   Comparison 1: Oral versus Intra-vaginal, Outcome 8: Time to first relief
 
Time to first relief
Study Data reported Results Notes
ACCELERATE 2002 Median time to initial relief
Proportion of patients at timepoints
Miconazole (intravaginal) treatment
group = 1.0 hour for individual symp-
toms and 4.0 hours for all symptoms
combined. Fluconazole (oral) treatment
group = 4.0 hours for individual symp-
toms and 16.0 hours for all symptoms
combined.
Miconazole treatment group = Initial
relief was reported by 16.0% of sub-
jects at 20 minutes following dosing, by
30.7% at 40 minutes, and by 96.0% of
subjects at 72 hours. Fluconazole treat-
ment group = Initial relief was reported
by 5.0% of subjects at 20 minutes fol-
lowing dosing, by 11.9% of subjects at
40 minutes, and by 90.1% of subjects at
72 hours.
favours intravaginal for individual and
all symptoms combined
Adetoro 1990 No specific data reported   “The rate or response to treatment sug-
gest that patients
receiving fluconazole (oral) or clotrim-
zole (intravaginal) experienced sympto-
matic
relief after one or two days of treat-
ment, respectively.
Andersen 1989 Median time to initial relief 1 day for fluconazole (oral) and 2
days for clotrimazole (intravaginal)
(P<0.001).
favors oral
Coric 2006 Proportion of patients at timepoints The onset of symptomatic relief in the
first 24 h of treatment was significantly
higher in the fluconazole (oral) (41 out
of 60) than in the clotrimazole (intrav-
aginal) group (9 out of 59).
favors oral
Mendling 2004 Median time to initial relief Time to first relief was similar in all
three treatment groups = 3 days.
no difference
Murina 2012 Mean time to initial relief Fenticonazole group = 2.3 days. Flu-
conazole = 4.5 days.
Vulvovaginal pruritus only.
favors intravaginal
Seidman 2005 Median time to initial relief
Proportion of patients at timepoints
Butoconazole (intravaginal) group =
17.5 hours. Fluconazole (oral) group =
22.9 hours. (p<0.001).
By 12- and 24-h post-treatment, 44.4%
and 72.8% of patients in the butocona-
zole treatment group reported first
relief of symptoms versus 29.1% and
55.7% of patients in the fluconazole
group (p= 0.044 and p= 0.024 respec-
tively).
favors intravaginal
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Slavin 1992 Median time to initial relief
Mean time to initial relief
Terconazole (intravaginal) median = 1.
Fluconazole (oral) median = 2.
Terconazole mean = 1.80 (SD 1.87). Flu-
conazole mean = 2.42 (SD 1.73).
favors intravaginal
Timonen 1992a Proportion of patients at timepoints 46.8% of the miconazole (intravagi-
nal) group had reported alleviation of
symptoms on the first day, compared to
51.9% of the fluconazole (oral) group.
97.9% of the miconazole group had re-
ported alleviation of symptoms by the
third day, compared to 85.2% of the flu-
conazole group. There was no statisti-
cal difference between the two groups.
alleviation of symptoms favors oral
(day 1) and intravaginal (day 3)
Tobin 1992 Mean time to initial relief Clotrimazole (intravaginal) group = 5.5





Comparison 2.   Oral versus Intra-vaginal (no. randomised)





Statistical method Effect size
2.1 Clinical cure (short term) 12 1630 Odds Ratio (M-H, Fixed, 95% CI) 1.10 [0.88, 1.38]
2.1.1 Fluconazole vs Clotrima-
zole
5 594 Odds Ratio (M-H, Fixed, 95% CI) 0.94 [0.66, 1.35]
2.1.2 Itraconazole vs Clotrima-
zole
2 337 Odds Ratio (M-H, Fixed, 95% CI) 1.50 [0.88, 2.54]
2.1.3 Fluconazole vs Miconazole 1 99 Odds Ratio (M-H, Fixed, 95% CI) 0.71 [0.28, 1.76]
2.1.4 Fluconazole vs Econazole 1 258 Odds Ratio (M-H, Fixed, 95% CI) 1.79 [0.90, 3.59]
2.1.5 Itraconazole vs Econazole 1 81 Odds Ratio (M-H, Fixed, 95% CI) 1.83 [0.73, 4.56]
2.1.6 Fluconazole vs Butocona-
zole
1 181 Odds Ratio (M-H, Fixed, 95% CI) 0.83 [0.46, 1.51]
2.1.7 Fluconazole vs Fenticona-
zole
1 80 Odds Ratio (M-H, Fixed, 95% CI) 0.89 [0.34, 2.33]
2.2 Clinical cure (long term) 8 972 Odds Ratio (M-H, Fixed, 95% CI) 1.17 [0.88, 1.56]
2.2.1 Fluconazole vs Clotrimzole 3 381 Odds Ratio (M-H, Fixed, 95% CI) 1.08 [0.68, 1.72]
2.2.2 Itraconazole vs Clotrima-
zole
1 73 Odds Ratio (M-H, Fixed, 95% CI) 1.28 [0.48, 3.44]
2.2.3 Fluconazole vs Miconazole 1 99 Odds Ratio (M-H, Fixed, 95% CI) 0.77 [0.30, 1.99]
2.2.4 Fluconazole vs Econazole 1 258 Odds Ratio (M-H, Fixed, 95% CI) 1.54 [0.93, 2.56]
2.2.5 Itraconazole vs Econazole 1 81 Odds Ratio (M-H, Fixed, 95% CI) 0.97 [0.34, 2.76]
2.2.6 fuconazole vs fenticona-
zole
1 80 Odds Ratio (M-H, Fixed, 95% CI) 0.65 [0.10, 4.11]
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Statistical method Effect size
2.3 Mycological cure (short
term)
16 2343 Odds Ratio (M-H, Fixed, 95% CI) 1.16 [0.96, 1.40]
2.3.1 Fluconazole vs Clotrima-
zole
10 1443 Odds Ratio (M-H, Fixed, 95% CI) 1.02 [0.80, 1.29]
2.3.2 Itraconazole vs Clotrima-
zole
2 337 Odds Ratio (M-H, Fixed, 95% CI) 1.12 [0.65, 1.92]
2.3.3 Fluconazole vs Miconazole 2 224 Odds Ratio (M-H, Fixed, 95% CI) 0.85 [0.44, 1.66]
2.3.4 Fluconazole vs Econazole 1 258 Odds Ratio (M-H, Fixed, 95% CI) 2.01 [1.14, 3.53]
2.3.5 Itraconazole vs Econazole 1 81 Odds Ratio (M-H, Fixed, 95% CI) 3.47 [1.35, 8.92]
2.4 Mycological cure (long term) 10 1378 Odds Ratio (M-H, Fixed, 95% CI) 1.35 [1.09, 1.68]
2.4.1 Fluconazole vs Clotrima-
zole
5 742 Odds Ratio (M-H, Fixed, 95% CI) 1.32 [0.99, 1.78]
2.4.2 Itraconazole vs Clotrima-
zole
1 73 Odds Ratio (M-H, Fixed, 95% CI) 0.87 [0.31, 2.44]
2.4.3 Fluconazole vs Miconazole 2 224 Odds Ratio (M-H, Fixed, 95% CI) 0.79 [0.45, 1.38]
2.4.4 Fluconazole vs Econazole 1 258 Odds Ratio (M-H, Fixed, 95% CI) 2.06 [1.26, 3.39]
2.4.5 Itraconazole vs Econazole 1 81 Odds Ratio (M-H, Fixed, 95% CI) 2.35 [0.96, 5.74]
2.5 Side effects 4 796 Odds Ratio (M-H, Fixed, 95% CI) 0.90 [0.55, 1.50]
2.5.1 Fluconazole vs Clotrima-
zole
1 142 Odds Ratio (M-H, Fixed, 95% CI) 1.67 [0.38, 7.26]
2.5.2 Itraconazole vs Clotrima-
zole
1 264 Odds Ratio (M-H, Fixed, 95% CI) 0.44 [0.16, 1.18]
2.5.3 Fluconazole vs Fenticona-
zole
1 80 Odds Ratio (M-H, Fixed, 95% CI) 1.54 [0.24, 9.75]
2.5.4 Fluconazole vs Miconazole 1 310 Odds Ratio (M-H, Fixed, 95% CI) 1.08 [0.53, 2.19]
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Analysis 2.1.   Comparison 2: Oral versus Intra-vaginal (no. randomised), Outcome 1: Clinical cure (short term)
Study or Subgroup








Heterogeneity: Chi² = 9.77, df = 4 (P = 0.04); I² = 59%
Test for overall effect: Z = 0.32 (P = 0.75)





Heterogeneity: Chi² = 0.16, df = 1 (P = 0.69); I² = 0%
Test for overall effect: Z = 1.50 (P = 0.13)





Test for overall effect: Z = 0.75 (P = 0.45)





Test for overall effect: Z = 1.65 (P = 0.10)





Test for overall effect: Z = 1.29 (P = 0.20)





Test for overall effect: Z = 0.61 (P = 0.54)











































































































M-H, Fixed, 95% CI
1.61 [0.49 , 5.28]
0.36 [0.07 , 1.91]
1.97 [0.97 , 4.00]
0.83 [0.47 , 1.46]
0.40 [0.16 , 1.00]
0.94 [0.66 , 1.35]
1.41 [0.76 , 2.61]
1.79 [0.65 , 4.99]
1.50 [0.88 , 2.54]
0.71 [0.28 , 1.76]
0.71 [0.28 , 1.76]
1.79 [0.90 , 3.59]
1.79 [0.90 , 3.59]
1.83 [0.73 , 4.56]
1.83 [0.73 , 4.56]
0.83 [0.46 , 1.51]
0.83 [0.46 , 1.51]
0.89 [0.34 , 2.33]
0.89 [0.34 , 2.33]
Odds Ratio
M-H, Fixed, 95% CI
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Test for overall effect: Z = 0.25 (P = 0.80)
Total (95% CI)
Total events:
Heterogeneity: Chi² = 16.89, df = 11 (P = 0.11); I² = 35%
Test for overall effect: Z = 0.84 (P = 0.40)











0.89 [0.34 , 2.33]
1.10 [0.88 , 1.38]
0.1 0.2 0.5 1 2 5 10
Favours intra-vaginal Favours oral
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Analysis 2.2.   Comparison 2: Oral versus Intra-vaginal (no. randomised), Outcome 2: Clinical cure (long term)
Study or Subgroup






Heterogeneity: Chi² = 1.22, df = 2 (P = 0.54); I² = 0%
Test for overall effect: Z = 0.33 (P = 0.74)





Test for overall effect: Z = 0.49 (P = 0.62)





Test for overall effect: Z = 0.54 (P = 0.59)





Test for overall effect: Z = 1.69 (P = 0.09)





Test for overall effect: Z = 0.06 (P = 0.95)





Test for overall effect: Z = 0.46 (P = 0.65)
Total (95% CI)
Total events:
Heterogeneity: Chi² = 3.78, df = 7 (P = 0.81); I² = 0%
Test for overall effect: Z = 1.07 (P = 0.28)




















































































M-H, Fixed, 95% CI
0.68 [0.12 , 3.83]
1.00 [0.59 , 1.71]
1.84 [0.60 , 5.67]
1.08 [0.68 , 1.72]
1.28 [0.48 , 3.44]
1.28 [0.48 , 3.44]
0.77 [0.30 , 1.99]
0.77 [0.30 , 1.99]
1.54 [0.93 , 2.56]
1.54 [0.93 , 2.56]
0.97 [0.34 , 2.76]
0.97 [0.34 , 2.76]
0.65 [0.10 , 4.11]
0.65 [0.10 , 4.11]
1.17 [0.88 , 1.56]
Odds Ratio
M-H, Fixed, 95% CI
0.1 0.2 0.5 1 2 5 10
Favours intra-vaginal Favours oral
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Analysis 2.3.   Comparison 2: Oral versus Intra-vaginal (no. randomised), Outcome 3: Mycological cure (short term)
Study or Subgroup













Heterogeneity: Chi² = 18.06, df = 9 (P = 0.03); I² = 50%
Test for overall effect: Z = 0.14 (P = 0.89)





Heterogeneity: Chi² = 2.24, df = 1 (P = 0.13); I² = 55%
Test for overall effect: Z = 0.42 (P = 0.68)





Heterogeneity: Chi² = 2.92, df = 1 (P = 0.09); I² = 66%
Test for overall effect: Z = 0.47 (P = 0.64)





Test for overall effect: Z = 2.42 (P = 0.02)





Test for overall effect: Z = 2.59 (P = 0.010)
Total (95% CI)
Total events:
Heterogeneity: Chi² = 33.48, df = 15 (P = 0.004); I² = 55%
Test for overall effect: Z = 1.52 (P = 0.13)























































































































M-H, Fixed, 95% CI
2.22 [0.46 , 10.79]
1.21 [0.76 , 1.94]
8.33 [0.78 , 89.47]
1.61 [0.49 , 5.28]
0.13 [0.02 , 0.78]
0.81 [0.51 , 1.27]
1.23 [0.41 , 3.65]
2.14 [0.96 , 4.79]
0.82 [0.45 , 1.49]
0.26 [0.05 , 1.21]
1.02 [0.80 , 1.29]
1.41 [0.76 , 2.61]
0.49 [0.14 , 1.69]
1.12 [0.65 , 1.92]
1.19 [0.56 , 2.55]
0.25 [0.05 , 1.27]
0.85 [0.44 , 1.66]
2.01 [1.14 , 3.53]
2.01 [1.14 , 3.53]
3.47 [1.35 , 8.92]
3.47 [1.35 , 8.92]
1.16 [0.96 , 1.40]
Odds Ratio
M-H, Fixed, 95% CI
0.1 0.2 0.5 1 2 5 10
Favours intra-vaginal Favours oral
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Analysis 2.3.   (Continued)
Test for overall effect: Z = 1.52 (P = 0.13)
Test for subgroup differences: Chi² = 10.84, df = 4 (P = 0.03), I² = 63.1%
Favours intra-vaginal Favours oral
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Analysis 2.4.   Comparison 2: Oral versus Intra-vaginal (no. randomised), Outcome 4: Mycological cure (long term)
Study or Subgroup








Heterogeneity: Chi² = 6.57, df = 4 (P = 0.16); I² = 39%
Test for overall effect: Z = 1.87 (P = 0.06)





Test for overall effect: Z = 0.26 (P = 0.79)





Heterogeneity: Chi² = 3.04, df = 1 (P = 0.08); I² = 67%
Test for overall effect: Z = 0.83 (P = 0.41)





Test for overall effect: Z = 2.86 (P = 0.004)





Test for overall effect: Z = 1.88 (P = 0.06)
Total (95% CI)
Total events:
Heterogeneity: Chi² = 17.95, df = 9 (P = 0.04); I² = 50%
Test for overall effect: Z = 2.73 (P = 0.006)

























































































M-H, Fixed, 95% CI
4.44 [0.98 , 20.07]
1.59 [1.05 , 2.41]
0.68 [0.12 , 3.83]
1.56 [0.57 , 4.24]
0.86 [0.51 , 1.45]
1.32 [0.99 , 1.78]
0.87 [0.31 , 2.44]
0.87 [0.31 , 2.44]
1.17 [0.57 , 2.40]
0.41 [0.16 , 1.05]
0.79 [0.45 , 1.38]
2.06 [1.26 , 3.39]
2.06 [1.26 , 3.39]
2.35 [0.96 , 5.74]
2.35 [0.96 , 5.74]
1.35 [1.09 , 1.68]
Odds Ratio
M-H, Fixed, 95% CI
0.1 0.2 0.5 1 2 5 10
Favours intra-vaginal Favours oral
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Analysis 2.5.   Comparison 2: Oral versus Intra-vaginal (no. randomised), Outcome 5: Side e;ects
Study or Subgroup





Test for overall effect: Z = 0.68 (P = 0.50)





Test for overall effect: Z = 1.63 (P = 0.10)





Test for overall effect: Z = 0.46 (P = 0.65)





Test for overall effect: Z = 0.20 (P = 0.84)
Total (95% CI)
Total events:
Heterogeneity: Chi² = 3.26, df = 3 (P = 0.35); I² = 8%
Test for overall effect: Z = 0.39 (P = 0.70)






















































M-H, Fixed, 95% CI
1.67 [0.38 , 7.26]
1.67 [0.38 , 7.26]
0.44 [0.16 , 1.18]
0.44 [0.16 , 1.18]
1.54 [0.24 , 9.75]
1.54 [0.24 , 9.75]
1.08 [0.53 , 2.19]
1.08 [0.53 , 2.19]
0.90 [0.55 , 1.50]
Odds Ratio
M-H, Fixed, 95% CI
0.05 0.2 1 5 20
Favours oral Favours intra-vaginal
 
 
Comparison 3.   Single-dose oral therapy versus 3 days intra-vaginal therapy





Statistical method Effect size
3.1 Mycological cure (short term) 4 618 Odds Ratio (M-H, Fixed, 95% CI) 1.11 [0.73, 1.69]
3.2 Mycological cure (long term) 3 509 Odds Ratio (M-H, Fixed, 95% CI) 1.19 [0.82, 1.73]
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Analysis 3.1.   Comparison 3: Single-dose oral therapy versus 3 days








Heterogeneity: Chi² = 1.74, df = 3 (P = 0.63); I² = 0%
Test for overall effect: Z = 0.49 (P = 0.62)


































M-H, Fixed, 95% CI
1.26 [0.71 , 2.24]
1.61 [0.49 , 5.28]
0.95 [0.37 , 2.49]
0.60 [0.18 , 1.92]
1.11 [0.73 , 1.69]
Odds Ratio
M-H, Fixed, 95% CI
0.1 0.2 0.5 1 2 5 10
Favours intra-vaginal Favours oral
 
 
Analysis 3.2.   Comparison 3: Single-dose oral therapy versus 3 days







Heterogeneity: Chi² = 3.03, df = 2 (P = 0.22); I² = 34%
Test for overall effect: Z = 0.93 (P = 0.35)





























M-H, Fixed, 95% CI
1.56 [0.97 , 2.53]
0.78 [0.35 , 1.75]
0.79 [0.32 , 1.95]
1.19 [0.82 , 1.73]
Odds Ratio
M-H, Fixed, 95% CI
0.1 0.2 0.5 1 2 5 10
Favours intra-vaginal Favours oral
 
 
Comparison 4.   Single-dose oral anti-fungal therapy versus single-dose intra-vaginal anti-fungal therapy





Statistical method Effect size
4.1 Clinical cure (short term) 4 572 Odds Ratio (M-H, Fixed, 95% CI) 0.74 [0.48, 1.14]
4.1.1 Fluconazole vs Clotrimazole 1 113 Odds Ratio (M-H, Fixed, 95% CI) 0.40 [0.16, 1.00]
4.1.2 Fluconazole vs Miconazole 1 93 Odds Ratio (M-H, Fixed, 95% CI) 1.23 [0.45, 3.42]
4.1.3 Fluconazole vs Econazole 1 230 Odds Ratio (M-H, Fixed, 95% CI) 1.51 [0.46, 4.89]
4.1.4 Fluconazole vs Butocona-
zole
1 136 Odds Ratio (M-H, Fixed, 95% CI) 0.66 [0.33, 1.30]
4.2 Clinical cure (long term) 2 270 Odds Ratio (M-H, Fixed, 95% CI) 1.24 [0.60, 2.54]
4.2.1 Fluconazole vs Miconazole 1 93 Odds Ratio (M-H, Fixed, 95% CI) 1.54 [0.51, 4.66]
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Statistical method Effect size
4.2.2 Fluconazole vs Econazole 1 177 Odds Ratio (M-H, Fixed, 95% CI) 1.05 [0.40, 2.72]
4.3 Mycological cure (short term) 6 737 Odds Ratio (M-H, Fixed, 95% CI) 1.16 [0.77, 1.74]
4.3.1 Fluconazole vs Clotrimazole 4 414 Odds Ratio (M-H, Fixed, 95% CI) 0.84 [0.50, 1.42]
4.3.2 Fluconazole vs Miconazole 1 93 Odds Ratio (M-H, Fixed, 95% CI) 1.75 [0.15, 20.00]
4.3.3 Fluconazole vs Econazole 1 230 Odds Ratio (M-H, Fixed, 95% CI) 1.93 [0.97, 3.83]
 
 
Analysis 4.1.   Comparison 4: Single-dose oral anti-fungal therapy versus single-
dose intra-vaginal anti-fungal therapy, Outcome 1: Clinical cure (short term)
Study or Subgroup





Test for overall effect: Z = 1.96 (P = 0.05)





Test for overall effect: Z = 0.40 (P = 0.69)





Test for overall effect: Z = 0.68 (P = 0.50)





Test for overall effect: Z = 1.21 (P = 0.23)
Total (95% CI)
Total events:
Heterogeneity: Chi² = 4.19, df = 3 (P = 0.24); I² = 28%
Test for overall effect: Z = 1.38 (P = 0.17)






















































M-H, Fixed, 95% CI
0.40 [0.16 , 1.00]
0.40 [0.16 , 1.00]
1.23 [0.45 , 3.42]
1.23 [0.45 , 3.42]
1.51 [0.46 , 4.89]
1.51 [0.46 , 4.89]
0.66 [0.33 , 1.30]
0.66 [0.33 , 1.30]
0.74 [0.48 , 1.14]
Odds Ratio
M-H, Fixed, 95% CI
0.1 0.2 0.5 1 2 5 10
Favours intra-vaginal Favours oral
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Analysis 4.2.   Comparison 4: Single-dose oral anti-fungal therapy versus single-
dose intra-vaginal anti-fungal therapy, Outcome 2: Clinical cure (long term)
Study or Subgroup





Test for overall effect: Z = 0.77 (P = 0.44)





Test for overall effect: Z = 0.10 (P = 0.92)
Total (95% CI)
Total events:
Heterogeneity: Chi² = 0.27, df = 1 (P = 0.60); I² = 0%
Test for overall effect: Z = 0.58 (P = 0.56)


































M-H, Fixed, 95% CI
1.54 [0.51 , 4.66]
1.54 [0.51 , 4.66]
1.05 [0.40 , 2.72]
1.05 [0.40 , 2.72]
1.24 [0.60 , 2.54]
Odds Ratio
M-H, Fixed, 95% CI
0.1 0.2 0.5 1 2 5 10
Favours intra-vaginal Favours oral
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Analysis 4.3.   Comparison 4: Single-dose oral anti-fungal therapy versus single-
dose intra-vaginal anti-fungal therapy, Outcome 3: Mycological cure (short term)
Study or Subgroup







Heterogeneity: Chi² = 5.70, df = 3 (P = 0.13); I² = 47%
Test for overall effect: Z = 0.65 (P = 0.52)





Test for overall effect: Z = 0.45 (P = 0.65)





Test for overall effect: Z = 1.88 (P = 0.06)
Total (95% CI)
Total events:
Heterogeneity: Chi² = 8.97, df = 5 (P = 0.11); I² = 44%
Test for overall effect: Z = 0.72 (P = 0.47)



























































M-H, Fixed, 95% CI
2.22 [0.46 , 10.79]
5.00 [0.42 , 59.66]
0.81 [0.42 , 1.56]
0.26 [0.05 , 1.21]
0.84 [0.50 , 1.42]
1.75 [0.15 , 20.00]
1.75 [0.15 , 20.00]
1.93 [0.97 , 3.83]
1.93 [0.97 , 3.83]
1.16 [0.77 , 1.74]
Odds Ratio
M-H, Fixed, 95% CI
0.1 0.2 0.5 1 2 5 10
Favours intra-vaginal Favours oral
 
 
Comparison 5.   Single-dose oral therapy versus 6-7 day intra-vaginal therapy





Statistical method Effect size
5.1 Clinical cure (short term) 3 427 Odds Ratio (M-H, Fixed, 95% CI) 1.57 [1.03, 2.42]
5.2 Clinical cure (long term) 2 266 Odds Ratio (M-H, Fixed, 95% CI) 0.99 [0.54, 1.83]
5.3 Mycological cure (short term) 4 527 Odds Ratio (M-H, Fixed, 95% CI) 1.47 [0.97, 2.21]
5.4 Mycological cure (long term) 3 366 Odds Ratio (M-H, Fixed, 95% CI) 1.36 [0.88, 2.10]
5.5 Side effects 1 142 Odds Ratio (M-H, Fixed, 95% CI) 1.67 [0.38, 7.26]
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Analysis 5.1.   Comparison 5: Single-dose oral therapy versus 6-7







Heterogeneity: Chi² = 1.03, df = 2 (P = 0.60); I² = 0%
Test for overall effect: Z = 2.07 (P = 0.04)





























M-H, Fixed, 95% CI
3.77 [0.15 , 95.82]
1.97 [0.97 , 4.00]
1.33 [0.77 , 2.30]
1.57 [1.03 , 2.42]
Odds Ratio
M-H, Fixed, 95% CI
0.1 0.2 0.5 1 2 5 10
Favours intra-vaginal Favours oral
 
 
Analysis 5.2.   Comparison 5: Single-dose oral therapy versus 6-7






Heterogeneity: Chi² = 1.12, df = 1 (P = 0.29); I² = 10%
Test for overall effect: Z = 0.04 (P = 0.97)
























M-H, Fixed, 95% CI
5.44 [0.21 , 144.10]
0.91 [0.48 , 1.71]
0.99 [0.54 , 1.83]
Odds Ratio
M-H, Fixed, 95% CI
0.1 0.2 0.5 1 2 5 10
Favours intra-vaginal Favours oral
 
 
Analysis 5.3.   Comparison 5: Single-dose oral therapy versus 6-7








Heterogeneity: Chi² = 2.25, df = 3 (P = 0.52); I² = 0%
Test for overall effect: Z = 1.82 (P = 0.07)


































M-H, Fixed, 95% CI
0.25 [0.01 , 5.98]
1.23 [0.50 , 3.02]
2.14 [0.96 , 4.79]
1.36 [0.76 , 2.44]
1.47 [0.97 , 2.21]
Odds Ratio
M-H, Fixed, 95% CI
0.1 0.2 0.5 1 2 5 10
Favours intra-vaginal Favours oral
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Analysis 5.4.   Comparison 5: Single-dose oral therapy versus 6-7







Heterogeneity: Chi² = 0.92, df = 2 (P = 0.63); I² = 0%
Test for overall effect: Z = 1.40 (P = 0.16)





























M-H, Fixed, 95% CI
5.44 [0.21 , 144.10]
1.56 [0.68 , 3.56]
1.23 [0.73 , 2.08]
1.36 [0.88 , 2.10]
Odds Ratio
M-H, Fixed, 95% CI
0.1 0.2 0.5 1 2 5 10
Favours intra-vaginal Favours oral
 
 






Test for overall effect: Z = 0.68 (P = 0.50)



















M-H, Fixed, 95% CI
1.67 [0.38 , 7.26]
1.67 [0.38 , 7.26]
Odds Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours oral Favours intra-vaginal
 
 
Comparison 6.   Fluconazole versus Clotrimazole





Statistical method Effect size
6.1 Long term clinical cure 3 438 Odds Ratio (M-H, Fixed, 95% CI) 0.91 [0.56, 1.46]
6.2 Long term mycological cure 7 940 Odds Ratio (M-H, Fixed, 95% CI) 1.25 [0.94, 1.65]
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Heterogeneity: Chi² = 1.26, df = 2 (P = 0.53); I² = 0%
Test for overall effect: Z = 0.39 (P = 0.69)





























M-H, Fixed, 95% CI
5.44 [0.21 , 144.10]
0.91 [0.48 , 1.71]
0.80 [0.37 , 1.71]
0.91 [0.56 , 1.46]
Odds Ratio
M-H, Fixed, 95% CI
0.1 0.2 0.5 1 2 5 10
Favours clotrimazole Favours fluconazole
 
 











Heterogeneity: Chi² = 9.73, df = 6 (P = 0.14); I² = 38%
Test for overall effect: Z = 1.55 (P = 0.12)

















































M-H, Fixed, 95% CI
4.44 [0.98 , 20.07]
1.56 [0.97 , 2.53]
5.44 [0.21 , 144.10]
1.56 [0.57 , 4.24]
0.78 [0.35 , 1.75]
1.23 [0.73 , 2.08]
0.52 [0.22 , 1.24]
1.25 [0.94 , 1.65]
Odds Ratio
M-H, Fixed, 95% CI
0.1 0.2 0.5 1 2 5 10
Favours clotrimazole Favours fluconazole
 
 
A D D I T I O N A L   T A B L E S
 
Study T1 T2 T3 T4
ACCELERATE 2002 7 - 10 days      
Adetoro 1990 8 days 32 days    
Andersen 1989 5 - 16 days 27 - 62 days    
Boag 1991 1 - 3 days 4 - 5 days 6 - 8 days 9 -12 days
Coric 2006 24 hours 14 days    
Goode 1992 2 weeks 4 weeks    
Mendling 2004 2 weeks 4 weeks 8 weeks  
Mikamo 1995 5 - 15 days 30 - 60 days    
Table 1.   Duration of follow-up (for primary and/or secondary outcome measures) 
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Murina 2012 7days 30 - 35    
O-Prasertsawat 1995 1 week 4 weeks    
Osser 1991 7 - 10 days 28 - 35 days 80 - 100
days
 
Roongpisuthipong 2010 7 days 28 days    
Sanam 2009 10 days      
Seidman 2005 hourly      
Sekhavat 2011 7 days 1 month    
Škerk V 2006 up to 2 months      
Slavin 1992 7 - 14 days 28 - 34 days    
Sobel 1995 14 days 35 days    
Stein 1991 1 week 4 weeks    
Stein 1993 7 - 10 days 30 - 35 days    
Timonen 1992a 1 week 2 weeks    
Timonen 1992b 1 week 1 month    
Tobin 1992 5 - 10 days 30 - 40 days    
Van Heusden 1990 6 - 10 days 22 - 60 days    
Van Heusden 1994 7 days 28 days    
Woolley 1995 7 - 10 days      





All comparisons Selection Bias Blinded Outcome Assessor Incomplete Outcome Data
Clinical cure
(short)
14 comparisons, OR 1.14,
95% CI [0.91, 1.43]
0/14 comparisons 1/14 comparisons, OR 1.70,
95% CI [0.64, 4.55]
12/14 comparisons, OR 1.22,
95% CI [0.95, 1.56]
Clinical cure
(long)
9 comparisons, OR 1.07,
95% CI [0.77, 1.50]
0/9 comparisons 1/9 comparisons, OR
0.69, 95% CI [0.20, 2.41]




20 comparisons, OR 1.24,
95% CI [1.03, 1.50]
1/20 comparisons,
OR 0.95, 95% CI
[0.37, 2.49]
1/20 comparisons, OR 3.55,
95% CI [1.29, 9.77]
15/20 comparisons, OR 1.41,
95% CI, [1.09, 1.82]
Table 2.   Sensitivity Analyses 
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Mycological
cure (long)
13 comparisons, OR 1.29,
95% CI [1.05, 1.60]
1/13 comparisons,
OR 0.78, 95% CI
[0.35, 1.75]
1/13 comparisons, OR 2.26,
95% CI [0.89, 5.74]
9/13 comparisons, OR 1.19, 95%
CI [0.90, 1.56],
Table 2.   Sensitivity Analyses  (Continued)
OR - odds ratio
95% CI - 95% percent confidence interval
Comparisons had to be rated as low risk of bias for both random allocation and allocation concealment to be included in the selection
bias sensitivity analysis. Comparisons for blinded outcome assessor and incomplete outcome data had to be rated as low risk of bias in
the respective categories. All sensitivity analyses are reported as odds ratio with 95% confidence intervals.
 
 
A P P E N D I C E S
Appendix 1. MEDLINE, Embase and CENTRAL search strategy update (2015-2018)
 
Database • MEDLINE
• MEDLINE In-Process & Other Non-Indexed Citations
• MEDLINE Daily Update
Platform Ovid
Search date 23/05/2018
Range of search date 2015 - 2018
Language Restrictions None
Other Limits Randomized clinical trials
Search strategy (results) 1 exp Imidazoles/ (251315)
2 exp Triazoles/ (33299)
3 exp Antifungal Agents/ (155439)
4 (butoconazole or clotrimazole or econazole).tw. (2981)
5 (fenticonazole or fluconazole or isoconazole).tw. (10938)
6 (itraconazole or miconazole or omoconazole).tw. (10034)
7 (oxiconazole or terconazole or tioconazole).tw. (345)
8 1 or 2 or 3 or 4 or 5 or 6 or 7 (420014)
9 exp Candidiasis, Vulvovaginal/ (3314)
10 ((vagina$ adj5 candidosis) or (vulvovagina$ adj5 candidosis) or (vagina$ adj5 mycoses) or (vagi-
na$ adj5 candidiasis) or (vulvovagina$ adj5 candidiasis) or (vagina$ adj5 mycoses) or (vagina$ adj5
thrush)).tw. (2281)
11 9 or 10 (4141)
12 randomized controlled trial.pt. (462300)
13 controlled clinical trial.pt. (92438)
14 (randomized or randomised).ti,ab. (531453)
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15 placebo.ti,ab. (194698)
16 clinical trials as topic.sh. (183855)
17 randomly.ti,ab. (292138)
18 trial.ti. (183315)
19 (crossover or cross-over or cross over).tw. (76612)
20 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 (1217979)
21 exp animals/ not humans.sh. (4463161)
22 20 not 21 (1122279)
23 8 and 11 and 22 (390)
24 limit 23 to yr="2015 -Current" (28)









Range of search date 2015-2018
Language Restrictions None
Other Limits Randomized clinical trials
Search strategy (results) 1. 'imidazole derivative'/exp (777386)
2. 'triazole derivative'/exp (147637)
3. 'antifungal agent'/exp (332564)
4. butoconazole:ab,ti OR clotrimazole:ab,ti OR econazole:ab,ti (3908)
5. fenticonazole:ab,ti OR fluconazole:ab,ti OR isoconazole:ab,ti (15085)
6. itraconazole:ab,ti OR miconazole:ab,ti OR omoconazole:ab,ti (13381)
7. oxiconazole:ab,ti OR terconazole:ab,ti OR tioconazole:ab,ti (504)
8. #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 (1064410)
9. 'vagina candidiasis'/exp (4869)
10. ((vagina* NEAR/5 candidosis):ab,ti) OR ((vulvovagina* NEAR/5 candidosis):ab,ti) OR ((vagina*
NEAR/5 candidiasis):ab,ti) OR ((vulvovagina* NEAR/5 candidiasis):ab,ti) OR ((vagina* NEAR/5 my-
coses):ab,ti) OR ((vagina* NEAR/5 thrush):ab,ti) (3134)
11. #9 OR #10 (5771)
12. 'randomized controlled trial'/de (497851)
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13. 'controlled clinical study'/de (426369)
14. random*:ti,ab (1288799)
15. 'randomization'/de (77741)
16. 'intermethod comparison'/de (234226)
17. placebo:ti,ab (269265)
18. compare:ti OR compared:ti OR comparison:ti (472043)
19. (evaluated:ab OR evaluate:ab OR evaluating:ab OR assessed:ab OR assess:ab) AND (compare:ab
OR compared:ab OR comparing:ab OR comparison:ab) (1726872)
20. (open NEAR/1 label):ti,ab (63503)
21. ((double OR single OR doubly OR singly) NEAR/1 (blind OR blinded OR blindly)):ti,ab (207173)
22. 'double blind procedure'/de (148746)
23. (parallel NEXT/1 group*):ti,ab (21432)
24. crossover:ti,ab OR 'cross over':ti,ab (91765)
25. ((assign* OR match OR matched OR allocation) NEAR/5 (alternate OR group* OR intervention*
OR patient* OR subject* OR participant*)):ti,ab (279205)
26. assigned:ti,ab OR allocated:ti,ab (327361)
27. (controlled NEAR/7 (study OR design OR trial)):ti,ab (291068)
28. volunteer:ti,ab OR volunteers:ti,ab (222766)
29. trial:ti249242
30. 'human experiment'/de (404507)
31. #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24
OR #25 OR #26 OR #27 OR #28 OR #29 OR #30 (4260415)
32. #8 AND #11 AND #31 (646)
33. #8 AND #11 AND #31 AND [embase]/lim AND [2015-2018]/py (109)






Database Cochrane Central Register of Controlled Trials
Platform Ovid
Search date 23/05/2018




Oral versus intra-vaginal imidazole and triazole anti-fungal treatment of uncomplicated vulvovaginal candidiasis (thrush) (Review)









Cochrane Database of Systematic Reviews
Search strategy (results) 1 exp Imidazoles/ (17051)
2 exp Triazoles/ (2174)
3 exp Antifungal Agents/ (6176)
4 (butoconazole or clotrimazole or econazole).tw. (476)
5 (fenticonazole or fluconazole or isoconazole).tw. (918)
6 (itraconazole or miconazole or omoconazole).tw. (997)
7 (oxiconazole or terconazole or tioconazole).tw. (76)
8 1 or 2 or 3 or 4 or 5 or 6 or 7 (24607)
9 exp Candidiasis, Vulvovaginal/ (259)
10 ((vagina$ adj5 candidosis) or (vulvovagina$ adj5 candidosis) or (vagina$ adj5 mycoses) or (vagi-
na$ adj5 candidiasis) or (vulvovagina$ adj5 candidiasis) or (vagina$ adj5 mycoses) or (vagina$ adj5
thrush)).tw. (380)
11 9 or 10 (459)
12 8 and 11 (341)
13 limit 12 to yr="2015 -Current" (33)





Appendix 2. MEDLINE, Embase and CENTRAL search strategy update (2018-2019)
 
Database § MEDLINE
§ MEDLINE In-Process & Other Non-Indexed Citations
§ MEDLINE Daily Update
Platform Ovid
Search date 29/08/2019
Range of search date 2018-2019
Language Restrictions None
Other Limits None
Search strategy (results) 1. (recurr$ adj5 herpes).tw. (1960)
2. exp Herpes Genitalis/ (4594)
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6. or/2-5 (88021)
7. recurr$.tw. (480861)
8. 6 and 7 (5095)
9. 1 or 8 (5095)
10. (short adj5 therapy).tw. (8549)
11. (short adj5 treatment).tw. (20480)
12. (short adj5 course).tw. (8582)
13. (short adj5 term).tw. (201653)
14. (short adj5 regimen).tw. (901)
15. (short adj5 cycle).tw. (1619)
16. (short adj5 strategy).tw. (1011)
17. (episodic adj5 therapy).tw. (175)
18. (episodic adj5 treatment).tw. (518)
19. (episodic adj5 course).tw. (215)
20. (episodic adj5 regimen).tw. (10)
21. (episodic adj5 cycle).tw. (26)
22. (episodic adj5 strategy).tw. (31)
23. or/10-22 (221262)
24. randomized controlled trial.pt. (487300)
25. controlled clinical trial.pt. (93205)
26. randomized.ab. (400631)
27. placebo.ab. (184378)
28. clinical trials as topic.sh. (188022)
29. randomly.ab. (275513)
30. trial.ti. (178802)
31. 24 or 25 or 26 or 27 or 28 or 29 or 30 (1130737)
32. exp animals/ not humans.sh. (4610034)
33. 31 not 32 (1031704)
34. 9 and 23 and 33 (55)
35. limit 34 to yr="2015 -Current" (3)
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Range of search date 2018-2019
Language Restrictions None
(Other Limits None
Search strategy (results) 1. 'imidazole derivative'/exp (853556)
2. 'triazole derivative'/exp (159845)
3. 'antifungal agent'/exp (355627)
4. butoconazole:ab,ti OR clotrimazole:ab,ti OR econazole:ab,ti (4113)
5. fenticonazole:ab,ti OR fluconazole:ab,ti OR isoconazole:ab,ti (16491)
6. itraconazole:ab,ti OR miconazole:ab,ti OR omoconazole:ab,ti (14377)
7. oxiconazole:ab,ti OR terconazole:ab,ti OR tioconazole:ab,ti (533)
8. #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #71161419
9. 'vagina candidiasis'/exp (5196)
10. ((vagina* NEAR/5 candidosis):ab,ti) OR ((vulvovagina* NEAR/5 candidosis):ab,ti) OR ((vagina*
NEAR/5 candidiasis):ab,ti) OR ((vulvovagina*NEAR/5 candidiasis):ab,ti) OR ((vagina* NEAR/5 my-
coses):ab,ti) OR ((vagina* NEAR/5 thrush):ab,ti) (3366)
11. #9 OR #10 (6135)
12. 'randomized controlled trial'/de (564076)
13. 'controlled clinical study'/de (427613)
14. random*:ti,ab (1438163)
15. 'randomization'/de (83269)
16. 'intermethod comparison'/de (252074)
17. placebo:ti,ab (292650)
18. compare:ti OR compared:ti OR comparison:ti (508934)
19. (evaluated:ab OR evaluate:ab OR evaluating:ab OR assessed:ab OR assess:ab) AND (compare:ab
OR compared:ab OR comparing:ab OR comparison:ab) (1963716)
20. (open NEAR/1 label):ti,ab (72969)
21. ((double OR single OR doubly OR singly) NEAR/1 (blind OR blinded OR blindly)):ti,ab (223924)
22. 'double blind procedure'/de (164124)
23. (parallel NEXT/1 group*):ti,ab (23905)
24. crossover:ti,ab OR 'cross over':ti,ab (99844)
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25. ((assign* OR match OR matched OR allocation) NEAR/5 (alternate OR group* OR intervention*
OR patient* OR subject* OR participant*)):ti,ab (310834)
26. assigned:ti,ab OR allocated:ti,ab (364001)
27. (controlled NEAR/7 (study OR design OR trial)):ti,ab (327118)
28. volunteer:ti,ab OR volunteers:ti,ab (238808)
29. trial:ti (283135)
30. 'human experiment'/de (462873)
31. #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24
OR #25 OR #26 OR #27 OR #28 OR #29OR #30 (4735963)
32. #8 AND #11 AND #31 (684)
#8 AND #11 AND #31 AND [embase]/lim AND [2018-2019]/py (55)









Range of search date 2018-2019
Language Restrictions None
Other Limits None
Search strategy (results) 1. exp Imidazoles/ (19488)
2. exp Triazoles/ (2412)
3. exp Antifungal Agents/ (7650)
4. (butoconazole or clotrimazole or econazole).tw. (607)
5. (fenticonazole or fluconazole or isoconazole).tw. (1193)
6. (itraconazole or miconazole or omoconazole).tw. (1271)
7. (oxiconazole or terconazole or tioconazole).tw. (89)
8. 1 or 2 or 3 or 4 or 5 or 6 or 7 (28893)
9. exp Candidiasis, Vulvovaginal/ (307)
10. ((vagina$ adj5 candidosis) or (vulvovagina$ adj5 candidosis) or (vagina$ adj5 mycoses) or (vagi-
na$ adj5 candidiasis) or (vulvovagina$ adj5 candidiasis) or (vagina$ adj5 mycoses) or (vagina$ adj5
thrush)).tw. (541)
11. 9 or 10 (627)
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12. 8 and 11 (440)
13. 13 limit 12 to yr="2018 -Current" (22)
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Outcome: Clinical cure - short term
15 RCT Agreed: main high risk is
due to lack of blinding
of participants and out-
comes Downgrade by -1
for serious concerns.
Agreed: low concern. While
some heterogeneity around
Analysis 1.1.1, the result is
no effect, which is the over-










they do not extend in-
to a very high or very
low odds ratio (OR)
range. The number of





Outcome: Clinical cure - long term














Outcome: Mycological cure - short term
19 RCT Agreed: minor concerns
and no downgrading. This
is more of an objective
measure and blinding may
be less important. There




Agreed: although there is
some heterogeneity present
here, it seems to be mainly
explained by the different
drugs in the comparisons.
Because there is a plausible
explanation for the hetero-






Agreed:there are a lot
of people in this analy-
sis, but the confidence
interval includes val-
ues that suggest al-
most no effect to val-
ues that suggest 50%
more likely to favour














































































































































































13 RCT Agreed: same as above Agreed: minor concern -
Analyisis 1.4.1 shows quite a
bit of heterogeneity within
the same drug comparison,





Agreed: same as above None Downgrade -1
to moderate
certainty
Outcome: Safety - withdrawals
3 RCT Agreed: the number of
withdrawals is small and
was the choice of health
professionals. No serious
concerns
Agreed: no forest plot, but
majority of studies had
no withdrawals, and the
two that did only had a
very small number of with-





Agreed: no CIs to as-
sess
None No downgrad-
ing - high cer-
tainty
Outcome: Side effects
17 RCT Agreed: side effects are
poorly defined in the stud-
ies, and assessment was
highly subjective meaning
it could have been influ-
enced by the lack of blind-
ing. Downgrade -1 for seri-
ous concerns.
Agreed: substantial hetero-
geneity across and with-
in subgroups. Serious con-





Agreed: while the con-
fidence intervals are
wide, they do not ex-
tend into a very high
or very low odds ratio
(OR) range. The num-
ber of people in the





by -2 to low
certainty
Outcome: Treatment preference
12 RCT Agreed: this is self-report
outcome and overall ROB
for the studies (5 high, 5
unclear and 2 low). If we
ignore the assessments
fo the blinding of the oth-
er outcomes we still have
the high and unclear judg-
ments - serious concerna
and downgrade -1
Agreed: no forest plot, but
the majority of studies
found the same result of
preference for oral treat-















-2 to low cer-
tainty








































































































































































10 RCT Agreed: assessment was
highly subjective meaning
it could have been influ-
enced by the lack of blind-
ing. Downgrade -1 for seri-
ous concerns
Agreed: difficult to assess
due to differences in report-
ing of data. Inconsistencies
can likely be explained by
the differences in how side
effects were assessed and
recorded between studies.
Because there is a plausible
explanation for the hetero-
geneity, Don't downgrade





Agreed: no CIs to as-




-2 to low cer-
tainty
Outcome: Costs
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[1] Indirectness includes consideration of:
• · Indirect (between study) comparisons
• · Indirect (surrogate) outcomes
• · Applicability (study populations, interventions or comparisons that are diDerent than those of interest)
[2] Other considerations for downgrading include publication bias. Other considerations for upgrading include a strong association with
no plausible confounders, a dose response relationship, and if all plausible confounders or biases would decrease the size of the eDect (if
there is evidence of an eDect), or increase it if there is evidence of no harmful eDect (safety)
[3]
Score 4 High certainty= This research provides a very good indication of the likely eDect. The likelihood that the eDect will be substantially
diDerent** is low.
Score 3 Moderate certainty = This research provides a good indication of the likely eDect. The likelihood that the eDect will be substantially
diDerent** is moderate.
Score 2 Low certainty = This research provides some indication of the likely eDect. However, the likelihood that it will be substantially
diDerent** is high.
Scpre 1 Very low certainty = This research does not provide a reliable indication of the likely eDect. The likelihood that the eDect will be
substantially diDerent** is very high.
** Substantially diDerent = a large enough diDerence that it might aDect a decision
W H A T ' S   N E W
 
Date Event Description
29 August 2019 New search has been performed This is the second update of the original review. The methods
and searches have been updated to current Cochrane standards.
There have been changes to the authorship with the addition of
six new authors. We searched for studies to 29 August 2019 and
identified seven new trials (ACCELERATE 2002; Coric 2006; Muri-
na 2012; Roongpisuthipong 2010; Sanam 2009; Sekhavat 2011;
Škerk V 2006). This review includes 26 trials.
29 August 2019 New citation required but conclusions
have not changed
The addition of new evidence does not change the conclusions
of the review. The results of this review should be considered
stable in terms of the antifungal medicines included. The fre-
quency of future updates should be limited. No further updates
are planned.
 
H I S T O R Y
Protocol first published: Issue 4, 2000
Review first published: Issue 1, 2001
 
Date Event Description
20 October 2015 Amended Final updated version submitted to STI group
15 September 2015 Amended An additional outcome, time to first relief, was added.
30 June 2015 New search has been performed The review was updated with data identified from searches con-
ducted on 18th June 2015. A new statistically significant differ-
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Date Event Description
ence was shown with long term mycological cure as a result of
the inclusion of the new studies.
11 November 2008 Amended Converted to new review format.
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D I F F E R E N C E S   B E T W E E N   P R O T O C O L   A N D   R E V I E W
At the 2020 update we updated the review methods to align with current Cochrane standards and these are now diDerent from those of the
published protocol and the last published version of the review (Nurbhai 2007). We used a fixed-eDect model only for the meta-analyses.
We also added safety and side eDects outcomes and have revised the review objective to reflect this. For the 'Risk of bias' assessment,
we increased the follow-up requirement from 80% to 90% for the incomplete outcome data (attrition bias) criterion. There have been
changes to the authorship with the addition of the following new authors: Hayley Denison, Alain Mayhew, Shakila Gnani Ramadoss, Clare
Robertson, Mary Ellen Schaafsma and Julia Worswick. Munira Nurbhai, Jill Mollison and Anne Ludbrook did not participate in this update.
I N D E X   T E R M S
Medical Subject Headings (MeSH)
Acute Disease;  Administration, Intravaginal;  Administration, Oral;  Antifungal Agents  [*administration & dosage]  [economics]; 
Candidiasis, Vulvovaginal  [*drug therapy];  Cost-Benefit Analysis;  Imidazoles  [administration & dosage]  [economics];  Randomized
Controlled Trials as Topic;  Triazoles  [administration & dosage]  [economics]
MeSH check words
Female; Humans
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